Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
BMC Cancer
    May 2026
  1. YANG G, Tian L, He D, Hu J, et al
    Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study.
    BMC Cancer. 2026 May 4. doi: 10.1186/s12885-026-16119.
    >> Share

    April 2026
  2. CHEN S, Yu J, Zhou Q, Li L, et al
    Trends in cardiovascular disease mortality among older adults with co-occuring lung cancer in the United States from 1999 to 2020.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16010.
    >> Share

  3. ZHANG M, Jiao T, Ma Y, Yang S, et al
    The dual role of baseline absolute eosinophil count in non-small cell lung cancer immunotherapy: a biomarker for enhanced efficacy and elevated risk of immune checkpoint inhibitor-related pneumonitis.
    BMC Cancer. 2026 Apr 27. doi: 10.1186/s12885-026-16104.
    >> Share

  4. YAMAGUCHI T, Shimizu J, Matsuzawa R, Shimomura K, et al
    Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.
    BMC Cancer. 2026 Apr 25. doi: 10.1186/s12885-026-15989.
    >> Share

  5. YIN X, He X, Guo W, Lu H, et al
    Prognostic value of CALLY index in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
    BMC Cancer. 2026 Apr 24. doi: 10.1186/s12885-026-16061.
    >> Share

  6. ZHANG Y, Li Z, Zeng A, Ma D, et al
    The influence of the administration sequence of neoadjuvant immunotherapy combined with chemotherapy on the postoperative pathological response of stage IIA-IIIB non-small cell lung cancer.
    BMC Cancer. 2026 Apr 22. doi: 10.1186/s12885-026-16028.
    >> Share

  7. MA HL, Zhao MD, Meng JM, Peng F, et al
    Sequential thoracic radiotherapy following immunotherapy in advanced non-small cell lung cancer: a real-world retrospective cohort study on efficacy and safety.
    BMC Cancer. 2026 Apr 20. doi: 10.1186/s12885-026-16035.
    >> Share

  8. ZHOU K, Bai Y, Deng L, Xie T, et al
    A multimodal immuno-radiologic model integrating circulating sPD-L1/CXCL9 and spectral CT iodine metrics to stratify postoperative relapse risk in non-small cell lung cancer.
    BMC Cancer. 2026 Apr 16. doi: 10.1186/s12885-026-16002.
    >> Share

  9. ZHAO L, Li J, Liu Y, Chen L, et al
    Global trends and projections of lung cancer attributable to residential radon exposure, 1990-2050.
    BMC Cancer. 2026 Apr 16. doi: 10.1186/s12885-026-15990.
    >> Share

  10. PHAM VH, Duong DC, Nguyen VB, Do HN, et al
    Real-world trends in diagnosis, treatment, and survival of non-small cell lung cancer in Vietnam.
    BMC Cancer. 2026 Apr 14. doi: 10.1186/s12885-026-15982.
    >> Share

  11. ERDIZCI P, Ersoz Kose E, Akyil M, Atinkaya Baytemir C, et al
    Comparison of prognosis between patients undergoing surgical resection and stereotactic ablative radiotherapy for early-stage lung cancer.
    BMC Cancer. 2026 Apr 14. doi: 10.1186/s12885-026-16008.
    >> Share

  12. WU Y, Cheng S, Huang Y, Kuang W, et al
    Multimodal prehabilitation management within the framework of enhanced recovery after surgery in patients undergoing lung cancer surgery: a scoping review.
    BMC Cancer. 2026 Apr 13. doi: 10.1186/s12885-026-15788.
    >> Share

  13. MAO Y, Wang A, Qin B, Zhai J, et al
    Efficacy and safety of low-intensity chemotherapy combined with immunotherapy in elderly patients with locally advanced and metastatic non-small cell lung cancer: a retrospective analysis.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15943.
    >> Share

  14. TENG H, Qin N, Liu K, Gong C, et al
    Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15996.
    >> Share

  15. CAO G, Di X, Liu X, Wang Z, et al
    Dose-effect relationship of D90 in iodine-125 seed implantation for advanced lung cancer: gradient-based efficacy and survival outcome.
    BMC Cancer. 2026 Apr 10. doi: 10.1186/s12885-026-15798.
    >> Share

  16. WEI T, Zhong G, Wang J, Huang C, et al
    Prognostic nutritional index improved the survival prediction of the revised Tokuhashi and Tomita scores for patients with lung cancer spinal metastases.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15952.
    >> Share

  17. VAZQUEZ-QUIROGA S, Garcia-Martinez S, Jimenez-Meseguer M, Irusta-Gonzalo A, et al
    Evaluation of the exposure-response relationship of pembrolizumab in non-small cell lung cancer: observational study protocol in real-world clinical practice.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15976.
    >> Share

  18. MA J, Zhu S, Li X, Gao S, et al
    A novel diagnostic model combining ProGRP and inflammatory biomarkers for early detection of lung cancer: development and validation in treatment-naive cohorts.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15961.
    >> Share

  19. TANG Y, Huang Y, Chen L, Huang Z, et al
    A preliminary study on the prognostic impact of platelet to monocyte ratio and its related genes on non-small cell lung cancer.
    BMC Cancer. 2026;26:451.
    >> Share

  20. YE L, Lou L, Yin Z, He T, et al
    Efficacy and safety of thoracoscopic photodynamic therapy combined with 5% ethanol-cisplatin intrapleural perfusion in the treatment of malignant pleural effusion in non-small cell lung cancer.
    BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15919.
    >> Share

  21. TURCOTT JG, Palomares-Palomares CB, Rios-Garcia E, Cardenas-Fernandez D, et al
    Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.
    BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15773.
    >> Share

  22. CHEN YF, Zhang CL, Li Y, Liu CF, et al
    Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15946.
    >> Share

  23. ROSENBERGER A, Bickeboller H, Christiani DC, Caporaso NE, et al
    Genes associated with genetic and rare lung diseases and the risk of lung cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15934.
    >> Share

    March 2026
  24. ZHANG D, Shi Y, Liu X, Gao X, et al
    Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.
    BMC Cancer. 2026 Mar 30. doi: 10.1186/s12885-026-15908.
    >> Share

  25. JAYAMANNE D, Suri T, Bergamin S, Metz G, et al
    Outcome analysis and associations with Charlson comorbidity index in the early-stage lung cancer patients treated with stereotactic radiotherapy.
    BMC Cancer. 2026 Mar 20. doi: 10.1186/s12885-026-15814.
    >> Share

  26. LEE KC, Shin H, Ohn J, Park JH, et al
    Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy.
    BMC Cancer. 2026 Mar 20. doi: 10.1186/s12885-026-15885.
    >> Share

  27. LI J, Tai Y, Pan B, Xiang L, et al
    Efficacy and prognostic factors of stereotactic radiosurgery versus whole-brain radiotherapy for brain metastases in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Mar 18. doi: 10.1186/s12885-026-15871.
    >> Share

  28. KAPADI A, Howard G, Merchant Z, Crosbie PAJ, et al
    Improving access and uptake of lung cancer screening with a focus on health inequity: the views of professionals involved in the UK NHS lung cancer screening programme.
    BMC Cancer. 2026 Mar 9. doi: 10.1186/s12885-026-15766.
    >> Share

  29. DAI P, Zhou H, Lian Q, Zhang Z, et al
    Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis.
    BMC Cancer. 2026 Mar 5. doi: 10.1186/s12885-026-15802.
    >> Share

  30. LI Y, Sun Z, Duan H, Song M, et al
    (125)Iodine brachytherapy stents for lung cancer with superior vena cava syndrome.
    BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15777.
    >> Share

  31. DA SILVA SARDENBERG RA, de Campos CAL, Porto BC, da Cruz JAS, et al
    Lung cancer treatment pathways in the largest private health insurance in Brazil: a real-world data study.
    BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15702.
    >> Share

    February 2026
  32. NAJAH Q, Makhlouf HA, Osman ASA, Almosilhy NA, et al
    Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer - a grade-assessed network meta-analysis of randomized controlled trials.
    BMC Cancer. 2026 Feb 27. doi: 10.1186/s12885-025-15439.
    >> Share

  33. WHITE LL, Maiyani M, Quintana LM, Powers JD, et al
    Use of cell-free DNA in early detection of lung cancer: a proof-of concept study.
    BMC Cancer. 2026 Feb 25. doi: 10.1186/s12885-026-15790.
    >> Share

  34. WU S, Zeng L, Li Y
    Single-cell hdWGCNA and experimental validation identify an innovative T-cell-associated prognostic model and immune microenvironment in lung adenocarcinoma with lymph node metastasis.
    BMC Cancer. 2026;26:426.
    >> Share

  35. QIAN H, Jiang J, Li S, Ni C, et al
    Efficacy and safety of nab-paclitaxel plus PD-1 inhibitor in elderly patients with advanced squamous lung cancer.
    BMC Cancer. 2026 Feb 21. doi: 10.1186/s12885-026-15767.
    >> Share

  36. LI Y, Ji Y, Wang C, Qin C, et al
    Prediction of immune checkpoint inhibitor-related pneumonitis in lung cancer: development and validation of multiple machine learning models.
    BMC Cancer. 2026 Feb 20. doi: 10.1186/s12885-026-15758.
    >> Share

  37. LU Y, Liu P, Ma C, Liu H, et al
    Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15738.
    >> Share

  38. ZHONG W, Wu S, Zhu R, Shi H, et al
    Optimal sequencing of brain radiotherapy and immunotherapy for patients with non-small cell lung cancer and driver gene-negative, asymptomatic brain metastases.
    BMC Cancer. 2026 Feb 15. doi: 10.1186/s12885-026-15706.
    >> Share

  39. DANG Y, Li X, Cheng Y, Pan S, et al
    Association between four indirect indicators of insulin resistance and lung cancer: evidence from UK biobank and Mendelian randomization analysis.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15697.
    >> Share

  40. MATSUURA S, Kita K, Matsushita K, Nagasaki T, et al
    Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors.
    BMC Cancer. 2026 Feb 12. doi: 10.1186/s12885-026-15733.
    >> Share

  41. TAO D, Lei H, Sun L, Wang L, et al
    Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients.
    BMC Cancer. 2026 Feb 12. doi: 10.1186/s12885-026-15729.
    >> Share

  42. WANG W, Hu X, Luan Y, Chen W, et al
    A multi-branch ensemble learning framework for detection of non-small cell lung cancer via T-cell receptor sequencing.
    BMC Cancer. 2026 Feb 11. doi: 10.1186/s12885-026-15714.
    >> Share

  43. KOURIE HR, Farhat C, Zouein J, Chebly A, et al
    Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-025-14839.
    >> Share

  44. MIYAMOTO I, Shimizu T, Hanamura M, Tanaka R, et al
    Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15646.
    >> Share

    January 2026
  45. LI Z, Gao X, Wang Q, Zhao Z, et al
    Genome-wide DNA methylation profiling reveals body mass Index-dependent epigenetic signatures associated with lung cancer susceptibility.
    BMC Cancer. 2026 Jan 28. doi: 10.1186/s12885-025-15536.
    >> Share

  46. BENBRAHIM Z, Siyouri O, Fetohi M, Benchakroun N, et al
    Brief report: immune checkpoint inhibitors use in lung cancer: a real-world outcome study in a middle-income country.
    BMC Cancer. 2026 Jan 26. doi: 10.1186/s12885-025-15008.
    >> Share

  47. SUN S, Zhang R, Tan S, Zhang Y, et al
    Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review.
    BMC Cancer. 2026 Jan 24. doi: 10.1186/s12885-026-15612.
    >> Share

  48. ZHANG W, Wu X, Sun X, Wen J, et al
    Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.
    BMC Cancer. 2026 Jan 23. doi: 10.1186/s12885-026-15616.
    >> Share

  49. LI F, Zhang C, Huang L, Wang Z, et al
    Neoadjuvant immunochemotherapy vs. neoadjuvant targeted therapy plus chemotherapy for EGFR-mutated non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2026 Jan 20. doi: 10.1186/s12885-026-15582.
    >> Share

  50. FENG Y, Qiao Y, Li H, Shen B, et al
    Investigating the causal link between metformin and lung cancer risk: a two-sample mendelian randomization analysis.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-025-15494.
    >> Share

  51. XIAO J, Zhu Z, Zhang F, Wang X, et al
    The potential of MMP14 as a prognostic and immune biomarker in lung cancer.
    BMC Cancer. 2026 Jan 17. doi: 10.1186/s12885-025-15539.
    >> Share

  52. ZHANG L, Jia H, Niu B
    Evaluating the efficacy and safety of antibody-drug conjugates in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 16. doi: 10.1186/s12885-025-15461.
    >> Share

  53. ZHANG Y, Xie M, Gao J, Ma X, et al
    High endothelial venules abundance in tertiary lymphoid structures: a prognostic biomarker in non-small cell lung cancer with neoadjuvant immunochemotherapy.
    BMC Cancer. 2026 Jan 15. doi: 10.1186/s12885-025-15529.
    >> Share

  54. LIU CY, Lin LF, Tsai CL, Huang TW, et al
    Baseline (1)(8)F-FDG PET/CT radiomics predict early progression and survival in small cell lung cancer.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-025-15523.
    >> Share

  55. ADAMSON B, van Boemmel-Wegmann S, Horne E, Soares S, et al
    Real-world evidence from Germany: representativeness analysis and mortality endpoint validation in electronic health record-derived oncology cohorts.
    BMC Cancer. 2026;26:202.
    >> Share

  56. XIA T, Zhang QX, Liu C, Wang ML, et al
    Elevated levels of SLC38A1 are correlated with an unfavorable prognosis, as well as accelerated cell proliferation and metastasis in lung adenocarcinoma.
    BMC Cancer. 2026;26:20.
    >> Share

  57. SHAO J, Zhang B, Yang S, Jin P, et al
    Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.
    BMC Cancer. 2026 Jan 5. doi: 10.1186/s12885-025-15509.
    >> Share

  58. ZHENG T, Li X, Jin J, Zhou L, et al
    Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 5. doi: 10.1186/s12885-025-15508.
    >> Share

  59. LIUFU Y, Su R, Wen Y, Guan Y, et al
    A CT-based deep learning approach to differentiate multiple primary lung cancers, metastases, and benign nodules.
    BMC Cancer. 2026;26:177.
    >> Share

    December 2025
  60. AVASTHI KK, Manley BJ, Pellini B, Zhang J, et al
    Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer.
    BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15492.
    >> Share

  61. WANG W, Xu X, Tian M, Han Q, et al
    Prognostic performance of the nutritional risk screening 2002 and the global leadership initiative on malnutrition in patients with lung cancer treated with immune checkpoint inhibitors.
    BMC Cancer. 2025;25:1893.
    >> Share

  62. LI R, Chen G, Shao Y, Jin X, et al
    Evaluating the value of circulating miR-21, miR-210 and miR-942 in the diagnosis of early-stage lung adenocarcinoma.
    BMC Cancer. 2025;25:1887.
    >> Share

  63. WANG Z, Meng J, Liu G, Wang Y, et al
    Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1909.
    >> Share

  64. JIN K, Qu Y, Li S, Sun C, et al
    A survival prediction model for leptomeningeal metastasis patients with non-small cell lung cancer based on deep learning.
    BMC Cancer. 2025 Dec 28. doi: 10.1186/s12885-025-15503.
    >> Share

  65. YANG J, Sun Y, Liang F, Shen Z, et al
    Network pharmacology analysis and in vitro experimental validation of liriodenine against non-small cell lung cancer.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15498.
    >> Share

  66. TAO Z, Li S, Xia H, Ni Z, et al
    Decoding anoikis-related genes in lung adenocarcinoma brainmetastasis via single-cell RNA sequencing: CD44-mediated functions.
    BMC Cancer. 2025;26:145.
    >> Share

  67. ALQASEM K, Alshwayyat S, Aljawabrah S, Maraqa K, et al
    Survival patterns and mutation profiles in never- and light-smokers with stage IV NSCLC.
    BMC Cancer. 2025;25:1906.
    >> Share

  68. XU J, Zhu A, Xu Y, Zhang Y, et al
    Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
    BMC Cancer. 2025;25:1879.
    >> Share

  69. HUANG P, Lin Z, Qiu Y, Chen D, et al
    Dual-layer spectral detector CT quantitative parameters and radiomics for predicting spread through air spaces of lung adenocarcinoma: a dual-center study.
    BMC Cancer. 2025;25:1905.
    >> Share

  70. YANO R, Tokito T, Murotani K, Murata D, et al
    Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15467.
    >> Share

  71. OI I, Fujita K, Imakita T, Okada Y, et al
    Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15479.
    >> Share

  72. SAHRAI H, Behnood J, Baradaran M, Khalaji A, et al
    Diagnostic accuracy of CT-based radiomics models in differentiating lung cancer from tuberculosis in pulmonary lesions: a systematic review and meta-analysis.
    BMC Cancer. 2025 Dec 17. doi: 10.1186/s12885-025-15446.
    >> Share

  73. HUANG M, Xiao W, Lin G, Li C, et al
    A contrastive learning method integrating pathological prior information for effective differentiation of histological categories in lung squamous cell carcinoma.
    BMC Cancer. 2025;26:114.
    >> Share

  74. YANG H, Han Y, Zhou X, Li J, et al
    The incidence and risk factors of pulmonary infection complications in lung cancer patients treated with immune checkpoint inhibitors.
    BMC Cancer. 2025;25:1871.
    >> Share

  75. BERRESSEM S, Moos LT, Roder J, Harzheim L, et al
    Uncovering gaps in personalised lung cancer care in Germany: a white spot analysis.
    BMC Cancer. 2025 Dec 12. doi: 10.1186/s12885-025-15411.
    >> Share

  76. AI J, Li H, Wang M, Zhao L, et al
    Development and validation of a CT-radiomics model for the diagnosis of lung cancer associated with cystic airspaces: a multicenter study.
    BMC Cancer. 2025 Dec 9. doi: 10.1186/s12885-025-15434.
    >> Share

  77. WEI Y, Li R, Liu X, Shi Y, et al
    Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.
    BMC Cancer. 2025 Dec 7. doi: 10.1186/s12885-025-15327.
    >> Share

  78. FAN X, Wang S, Li W, Wang R, et al
    Quantifying interplay effects in lung cancer IMPT: a comprehensive analysis of treatment planning parameter sensitivity.
    BMC Cancer. 2025 Dec 5. doi: 10.1186/s12885-025-15416.
    >> Share

  79. FU S, Li L, Ou Z, Lin C, et al
    Retrospective analysis of the clinical features and prognosis of idiopathic pulmonary fibrosis combined with lung cancer.
    BMC Cancer. 2025;25:1854.
    >> Share

  80. SHI Y, Lei Y, Liu Y, Zhao W, et al
    Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15259.
    >> Share

  81. BUGDAY I, Inanc M, Ozkan M, Bozkurt O, et al
    Prognostic role of prognostic nutritional index change in patients with extensive stage small cell lung cancer treated with platinum-based chemotherapy.
    BMC Cancer. 2025;25:1846.
    >> Share

  82. ZHANG X, Li W, Du Y, Zhang Y, et al
    A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer.
    BMC Cancer. 2025;25:1848.
    >> Share

  83. LI Q, Liu R, Han L, Xu Y, et al
    Analysis of setup error and setup efficiency in SBRT for non-small cell lung cancer via a surface-guided radiation therapy system.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15353.
    >> Share

  84. RAO Y, Rao H, Rao Y, Wu X, et al
    First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs.
    BMC Cancer. 2025;26:46.
    >> Share

    November 2025
  85. LI Y, Xu R, Xian J, Wang Z, et al
    Development and validation of a predictive model for recurrence in postoperative patients with stage ?A1-?A non-small cell lung cancer.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15275.
    >> Share

  86. ZHANG M, Di Y, Liu Z, Yan M, et al
    IGFBP1 facilitates tumor proliferation, invasion and migration by modulating the MAPK-ERK signaling pathway in lung adenocarcinoma.
    BMC Cancer. 2025;25:1924.
    >> Share

  87. NAM JW, Kim SE, Lee KM, Jung YW, et al
    Association between body-mass index change and lung cancer risk in Korea: nested case-control study.
    BMC Cancer. 2025;25:1805.
    >> Share

  88. WU CH, Wu X, Hu X, Kennedy A, et al
    Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients.
    BMC Cancer. 2025 Nov 22. doi: 10.1186/s12885-025-15295.
    >> Share

  89. LI F, Li F, Lu H, Zhao D, et al
    A comparative study on prognostic differences between men and women with non-small cell lung cancer across different antitumor treatment modalities.
    BMC Cancer. 2025;25:1802.
    >> Share

  90. SU T, Li L, Jing C, Chen L, et al
    KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis.
    BMC Cancer. 2025;25:1794.
    >> Share

  91. ZHANG Y, Li W, Zhang W, Xing S, et al
    Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study.
    BMC Cancer. 2025;25:1785.
    >> Share

  92. NING G, Sihan C, Daihong J, Zhilong Z, et al
    Effect of position management combined with active cycle of breathing techniques on reducing postoperative pulmonary complications in lung cancer patients.
    BMC Cancer. 2025;25:1780.
    >> Share

  93. PARK SE, Hwang IG, Choi JH
    Skeletal muscle loss and associated clinical outcomes in patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
    BMC Cancer. 2025;25:1772.
    >> Share

  94. BAI M, Li J
    Lung cancer and COVID-19 susceptibility and severity: a Mendelian randomization analysis.
    BMC Cancer. 2025;25:1771.
    >> Share

  95. MEI T, Wang T, Zhou Q
    Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1767.
    >> Share

  96. KE Z, Xu H, Shen K, Wen Y, et al
    KAT2A: a prognostic biomarker influencing proliferation and immune escape in lung adenocarcinoma.
    BMC Cancer. 2025;25:1753.
    >> Share

  97. LI H, Ding L, Li N, Hong X, et al
    Unraveling the nexus between lung cancer and rheumatoid arthritis using integrative transcriptomics and genomics.
    BMC Cancer. 2025;25:1758.
    >> Share

  98. CHEN Z, Wang Y, Shi M, Qi K, et al
    Risk factors and predictive model of lymph node metastasis in clinical stage IA peripheral non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2025;25:1742.
    >> Share

  99. WANG Y, Su Y, Li J, Xie D, et al
    Machine learning-based differentiation of benign and malignant adrenal lesions using 18F-FDG PET/CT: a two-stage classification and SHAP interpretation study.
    BMC Cancer. 2025;25:1726.
    >> Share

  100. REYES-REYES E, Cuetara-Lugo E, Herrera-Isidron JA, Perez-Benitez M, et al
    Polymorphisms in DNA repair related genes as risk factors for lung cancer in Cuban population: a case control study.
    BMC Cancer. 2025;25:1717.
    >> Share

  101. FU YL, Tang ZY, Zhu YY, Liu QW, et al
    Clinical significance and minimal clinically important differences for the survival outcomes in randomized clinical trials of lung cancer.
    BMC Cancer. 2025;25:1712.
    >> Share

    October 2025
  102. FUETH M, Christoffel J, Harati K, Reinkemeier F, et al
    Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models.
    BMC Cancer. 2025;25:1680.
    >> Share

  103. BAO T, Li X, Deng Y, Chen L, et al
    Comparing radiomics, deep learning, and fusion models for predicting occult pleural dissemination in patients with non-small cell lung cancer: a retrospective multicenter study.
    BMC Cancer. 2025;25:1670.
    >> Share

  104. HIRAI T, Horie Y, Kitamura T
    Summary of present design of discrete choice experiments for patient preferences in lung cancer based on the ISPOR ESTIMATE checklist.
    BMC Cancer. 2025;25:1649.
    >> Share

  105. ZHANG Y, Zhang Q, Wang L, Hu Y, et al
    The value of second-generation gene sequencing in lung cancer immunotherapy with concurrent infections.
    BMC Cancer. 2025;25:1636.
    >> Share

  106. MOKHTARI V, Hashemi M, Marandi SJ, Jebali A, et al
    Design, synthesis, and evaluation of A therapeutic vaccine candidate against lung cancer based on multi-epitopes of MAGE-A3, TGF-beta2, and VEGF-A.
    BMC Cancer. 2025;25:1632.
    >> Share

  107. SHIN JE, Park S, Jung HA, Sun JM, et al
    Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study.
    BMC Cancer. 2025;25:1616.
    >> Share

  108. LI H, Li P, Zhu S, Hou W, et al
    Different detection rates of brain metastasis in different pathological types of lung cancer by (18)F-FAPI PET/CT.
    BMC Cancer. 2025;25:1620.
    >> Share

  109. QU F, Wang J, Zhao Q, Jiang H, et al
    Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma.
    BMC Cancer. 2025;25:1593.
    >> Share

  110. PAN M, Yuan Y, Chen Z, Dan Y, et al
    Association between triglyceride-glucose index and pathological invasiveness of lung adenocarcinoma in patients with solitary ground-glass nodules: a cross-sectional study.
    BMC Cancer. 2025;25:1584.
    >> Share

  111. ZHANG Q, Xu J, Deng S, Li X, et al
    Efficacy of brain radiotherapy combined with atezolizumab and platinum-doublet chemotherapy for advanced non-small-cell lung cancer with brain metastases: a pooled analysis.
    BMC Cancer. 2025;25:1568.
    >> Share

  112. MORIKAWA K, Takashima Y, Oki M, Tsuzuku A, et al
    Prospective multicenter validation of a next-generation sequencing panel using cytology specimens for lung cancer: cPANEL.
    BMC Cancer. 2025;25:1538.
    >> Share

  113. FANG J, Li Q, Xu N, Yang X, et al
    Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma.
    BMC Cancer. 2025;25:1543.
    >> Share

  114. NAUREEN F, Shah Y, Rehman MU, Fazli Nasir FN, et al
    Innovative inhalable dry powder: nanoparticles loaded with Crizotinib for targeted lung cancer therapy.
    BMC Cancer. 2025;25:1526.
    >> Share

  115. WANGSUBTAWEE S, Thamrongjirapat T, Trachu N, Incharoen P, et al
    The impact of systemic inflammatory markers on EGFR-mutant non-small cell lung cancer.
    BMC Cancer. 2025;25:1510.
    >> Share

  116. WANG K, An L, Zang A, Huo Y, et al
    Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35.
    BMC Cancer. 2025;25:1504.
    >> Share

  117. WEN J, Yun W, Yin X, Meng X, et al
    Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma.
    BMC Cancer. 2025;25:1507.
    >> Share

  118. CHEN X, Xiao X, Wang M, Mei T, et al
    Development and validation of a dynamic nomogram for predicting brain metastasis in stage III NSCLC patients undergoing definitive chemoradiotherapy.
    BMC Cancer. 2025;25:1500.
    >> Share

    September 2025
  119. YANG X, He Y, Guo T, Fang J, et al
    The efficacy analysis of neoadjuvant chemoimmunotherapy followed by surgery in stage III locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1443.
    >> Share

  120. BOLEK H, Kayaalp M, Sahin TK, Dogan OT, et al
    Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma.
    BMC Cancer. 2025;25:1451.
    >> Share

  121. ZHONG J, Han X, Lofters A, Singh J, et al
    Lung cancer stage at diagnosis and immigrant English/French language proficiency: a retrospective population level cohort study of urban residents in Ontario, Canada.
    BMC Cancer. 2025;25:1452.
    >> Share

  122. OBATA T, Norikane T, Manabe Y, Murao M, et al
    Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.
    BMC Cancer. 2025;25:1454.
    >> Share

  123. QIN L, Zhao L, Li XM, Jia QC, et al
    A CT-based radiomics nomogram incorporating adipose tissue to differentiate invasive adenocarcinomas among part-solid pulmonary nodules.
    BMC Cancer. 2025;25:1471.
    >> Share

  124. HUANG Y, Yuan X, Xu L, Jian J, et al
    Automated contouring of gross tumor volume lymph nodes in lung cancer by deep learning.
    BMC Cancer. 2025;25:1444.
    >> Share

  125. KATSUSHIMA U, Fukushima T, Nakano J, Fujii K, et al
    Combined effects of slow movement training with tonic force generation and aerobic exercise prior to cancer therapy in patients with lung cancer (START-lung): a pilot feasibility trial.
    BMC Cancer. 2025;25:1438.
    >> Share

  126. ABDEL-HAFEZ SH, Alexeree SMI
    Evaluating the anticancer properties of VAF: a novel folate-alpha-tocopherol conjugate against lung cancer cells.
    BMC Cancer. 2025;25:1423.
    >> Share

  127. MCMILLAN MT, Reyngold M, Crane CH, O'Brien DAR, et al
    A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).
    BMC Cancer. 2025;25:1408.
    >> Share

  128. LIU X, Lu F, Yang H, Liao G, et al
    Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study.
    BMC Cancer. 2025;25:1415.
    >> Share

  129. LI L, Feng Q, Jiang Y, Yang L, et al
    KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axis.
    BMC Cancer. 2025;25:1417.
    >> Share

  130. HE Y, Che S, Xie J, Zhu W, et al
    Relationships between growth rate and Ki-67 and immune indices in ground-glass nodule-featured lung adenocarcinoma.
    BMC Cancer. 2025;25:686.
    >> Share

    August 2025
  131. BAO T, Deng Y, Chen L, Sun W, et al
    Correction: Primary tumour resection in non-small cell lung cancer patients with pleural dissemination unexpectedly detected during operation: a two-centre retrospective cohort study.
    BMC Cancer. 2025;25:1398.
    >> Share

  132. MANIWA H, Naito M, Ono M, Suyama N, et al
    Decreased 6-minute walk distance after pulmonary resection increases the risk of postoperative hospital re-admission: a retrospective cohort study.
    BMC Cancer. 2025;25:1397.
    >> Share

  133. FUKUI T, Imamura Y, Kakutani T, Uryu K, et al
    Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.
    BMC Cancer. 2025;25:1379.
    >> Share

  134. HE X, Shi M, Zhang L, Zhan J, et al
    Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.
    BMC Cancer. 2025;25:1380.
    >> Share

  135. DUDOV A, Conev N, Petrova M, Tonev I, et al
    Bulgarian exploratory analysis of time from diagnosis to treatment of lung cancer patients (Beat) - a retrospective database study on the patient pathway and time from diagnosis to treatment.
    BMC Cancer. 2025;25:1384.
    >> Share

  136. YI C, Jiang S, Xiong L, Yang J, et al
    D-S-Net: an efficient dual-stage strategy for high-precision segmentation of gross tumor volumes in lung cancer CT images.
    BMC Cancer. 2025;25:1387.
    >> Share

  137. TAN Y, Song Q
    Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system.
    BMC Cancer. 2025;25:1360.
    >> Share

  138. OUYANG T, Zhang F, Yang Y, Luo T, et al
    Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers.
    BMC Cancer. 2025;25:1353.
    >> Share

  139. ZHAO W, Li B, Gu Y, Jin X, et al
    The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1332.
    >> Share

  140. ZENG Y, Wang Q, Qiao D, Dai B, et al
    METTL16-dependent GPX4 m(6)A modification links ferroptosis to NSCLC TKIs resistance.
    BMC Cancer. 2025;25:1335.
    >> Share

  141. WANG X, Liang H, Du Q, Li Y, et al
    HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis.
    BMC Cancer. 2025;25:1317.
    >> Share

  142. JAPUNTICH SJ, Sacasa NG, Cameron S, Balletto B, et al
    Lung cancer screening experiences among patients with a smoking history and primary care providers: a qualitative study.
    BMC Cancer. 2025;25:1305.
    >> Share

  143. LIN X, Liu S, Ding Y, Zhao J, et al
    Contrasting tracheal, bronchus, and lung cancer burdens and care quality: a comparative analysis of China and global trends.
    BMC Cancer. 2025;25:1298.
    >> Share

  144. JIANG Z, Zhao F, Li B, He J, et al
    Multidimensional comparative evaluation of first-line therapies for extensive-stage small cell lung cancer: a systematic review and network meta-analysis of clinical efficacy and safety profiles.
    BMC Cancer. 2025;25:1292.
    >> Share

  145. LOBINGER D, Taylor N, Messner V, Seier S, et al
    Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse in thoracic cancer.
    BMC Cancer. 2025;25:1297.
    >> Share

  146. LUAN X, Han X, Wang Z, Zhao L, et al
    Heterogeneity of metastatic gastric cancer: solitary non-regional lymph node metastasis and solitary lung metastasis showed better survival outcomes than other metastatic patterns.
    BMC Cancer. 2025;25:1287.
    >> Share

  147. PENG Z, Wang Y, Qi Y, Hu H, et al
    Application of prediction model based on CT radiomics in prognosis of patients with non-small cell lung cancer.
    BMC Cancer. 2025;25:1273.
    >> Share

    July 2025
  148. OLAYODE OO, Ogunoye BT, Oladeji EO, Olayinka OE, et al
    Cerebrospinal fluid Circulating Tumor DNA (ctDNA) as a biomarker for CNS metastases in Non-Small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods.
    BMC Cancer. 2025;25:1246.
    >> Share

  149. LI F, Li F, Lu H, Zhao D, et al
    Analysis of age-related survival differences in advanced non-small cell lung cancer patients based on real-world data.
    BMC Cancer. 2025;25:1244.
    >> Share

  150. KO MM, Na SW, Yi JM, Jang H, et al
    Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.
    BMC Cancer. 2025;25:1229.
    >> Share

  151. CHEN Z, Tang C, Ma X, Tian P, et al
    Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China.
    BMC Cancer. 2025;25:1216.
    >> Share

  152. SHAN X, Wang W, Zhang T, Liu W, et al
    Comparison the efficiency of whole brain radiotherapy and simultaneous integrated boost in small cell lung cancer with brain metastases.
    BMC Cancer. 2025;25:1210.
    >> Share

  153. MA F, Xie Y, Lei Y, Kuang Z, et al
    Retraction Note: The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.
    BMC Cancer. 2025;25:1198.
    >> Share

  154. LIU M, Huang S, Yu Z, Dai L, et al
    Assessing factors influencing participation in LDCT lung cancer screening among high-risk urban populations in Nanjing, China.
    BMC Cancer. 2025;25:1196.
    >> Share

  155. ZHANG X, He M, Zheng G, Bai J, et al
    The impact of stratified management of Ki-67 on the prognosis of small-cell lung cancer.
    BMC Cancer. 2025;25:1197.
    >> Share

  156. WANG X, Yang J, E J, Liu F, et al
    Imaging features and prognostic significance of immune checkpoint inhibitor-related pneumonitis in NSCLC.
    BMC Cancer. 2025;25:1192.
    >> Share

  157. PENG J, Zhou J, Liu G, Kang P, et al
    Alterations and correlation between DNA damage and repair response and PD-L1 expression in non-small cell lung cancers.
    BMC Cancer. 2025;25:1183.
    >> Share

  158. GAO M, Su M, Wang J, Wang R, et al
    Immunotherapy combined with radiotherapy in the treatment of lung cancer: a meta-analysis of therapeutic effectiveness, safety considerations, and abscopal effect.
    BMC Cancer. 2025;25:1184.
    >> Share

  159. GORLOVA OY, Gorlov IP, Ripley RT, Cheng C, et al
    Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes.
    BMC Cancer. 2025;25:1169.
    >> Share

  160. YANG L, Li Y, Zeng T, Long M, et al
    Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.
    BMC Cancer. 2025;25:1163.
    >> Share

  161. DAI F, Mao C, Guo G, Mei L, et al
    Predicting exploratory thoracotomy in non-small cell lung cancer: a computed tomography based nomogram approach.
    BMC Cancer. 2025;25:1161.
    >> Share

  162. SHUAI Y, Liu J, Yang Y, Huang X, et al
    Neoadjuvant immunochemotherapy versus chemotherapy for elderly patients with IB-IIIB non-small-cell lung cancer in real-world practice.
    BMC Cancer. 2025;25:1150.
    >> Share

  163. NIU Y, Jia HB, Li XM, Huang WJ, et al
    Deep learning radiomics and mediastinal adipose tissue-based nomogram for preoperative prediction of postoperative? brain metastasis risk in non-small cell lung cancer.
    BMC Cancer. 2025;25:1133.
    >> Share

  164. WANG XC, Xu XL, Wang SY, Cheng H, et al
    Nomogram based on the advanced lung cancer inflammation index and other relevant clinical factors for patients with cervical squamous cell carcinoma undergoing concurrent chemoradiotherapy.
    BMC Cancer. 2025;25:1043.
    >> Share

  165. GUO LW, Lyu ZY, Liu Y, Meng QC, et al
    The probability of lung cancer in patients with pulmonary nodules detected via low-dose computed tomography screening in China.
    BMC Cancer. 2025;25:1058.
    >> Share

  166. LONG L, Jiang L, Teng Y, Yang D, et al
    Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer.
    BMC Cancer. 2025;25:1077.
    >> Share

  167. ZHAO L, Xiong Q, Long Y, Hu H, et al
    Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study.
    BMC Cancer. 2025;25:1136.
    >> Share

  168. LIU M, Yang F, Tang B, Xin X, et al
    Steps towards overcoming challenges in clinical practice at 1.5T MR-Linac for lung cancer adaptive radiotherapy.
    BMC Cancer. 2025;25:1034.
    >> Share

  169. ZHANG J, Wu Z, Wang S, Sun Y, et al
    Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer.
    BMC Cancer. 2025;25:1070.
    >> Share

  170. FAIZI MK, Qiang Y, Wei Y, Qiao Y, et al
    Deep learning-based lung cancer classification of CT images.
    BMC Cancer. 2025;25:1056.
    >> Share

    June 2025
  171. CHEN H, Yu Y, Zhu S, Zhao J, et al
    Correction: Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.
    BMC Cancer. 2025;25:1019.
    >> Share

  172. WANG Y, Su X, Jia J, Zhou T, et al
    Early radiotherapy improved survival of patients with extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy.
    BMC Cancer. 2025;25:1012.
    >> Share

  173. TONG X, Zhu T, Ma L, Yang X, et al
    Cathepsin C correlates with M2 macrophage infiltration and regulates the tumor growth and metastasis in non-small cell lung cancer.
    BMC Cancer. 2025;25:1001.
    >> Share

  174. SAEED R, McSorley S, Cascales A, McMillan DC, et al
    The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:994.
    >> Share

  175. LI H, Lu Y, Chen H, Li T, et al
    Identification and validation of a DNA methylation-block prognostic model in non-small cell lung cancer patients.
    BMC Cancer. 2025;25:999.
    >> Share

  176. WASILEWSKI D, Shaked Z, Fuchs A, Roohani S, et al
    Re-resection of brain metastases - outcomes of an institutional cohort study and literature review.
    BMC Cancer. 2025;25:973.
    >> Share

    May 2025
  177. RENAUD S, Casabianca P, Diez-Andreu P, Chartier M, et al
    Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study.
    BMC Cancer. 2025;25:966.
    >> Share

  178. XING H, Wu C, Yang W, Cai S, et al
    Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.
    BMC Cancer. 2025;25:954.
    >> Share

  179. MENG H, Ding RQ, Jia L, Chen XP, et al
    Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.
    BMC Cancer. 2025;25:960.
    >> Share

  180. CHEN H, Yu Y, Zhu S, Zhao J, et al
    Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.
    BMC Cancer. 2025;25:948.
    >> Share

  181. TAN M, Li L, Tan B, Yang J, et al
    Innovations in modern low-LET radiotherapy regimens for locally advanced non-small cell lung cancer: a meta-analysis and systematic review of high-dose-rate brachytherapy, stereotactic body radiotherapy, and hypofractionated proton therapy.
    BMC Cancer. 2025;25:942.
    >> Share

  182. WU S, Qiu Z, Shi H, Yu W, et al
    High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy.
    BMC Cancer. 2025;25:926.
    >> Share

  183. HONG M, Yun I, Moon JY
    Impact of doctor-shopping behavior on patient survival in lung cancer: findings from a 11-year cohort study using Korean claims data.
    BMC Cancer. 2025;25:914.
    >> Share

  184. YANG S, Liu Y, Zhao J, He Z, et al
    EGFR exon 20 insertions mutation in lung adenocarcinoma and its response by high-dose of Furmonertinib: a real-world study.
    BMC Cancer. 2025;25:900.
    >> Share

  185. ZHENG C, Miao J, Xu L, Cai Y, et al
    Novel PET imaging biomarkers as predictors of postoperative recurrence in lung adenocarcinoma.
    BMC Cancer. 2025;25:874.
    >> Share

  186. CHEN X, Wang K, Liao Y, Zheng C, et al
    Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis.
    BMC Cancer. 2025;25:862.
    >> Share

  187. YAO J, Geng Y, Xu J, Zou B, et al
    The impact of EGFR mutation and PD-L1 status on the efficacy of postoperative radiotherapy in stage III-pN2 NSCLC.
    BMC Cancer. 2025;25:858.
    >> Share

  188. ZHAO S, Du X, Zhang Y, Bai J, et al
    Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens.
    BMC Cancer. 2025;25:842.
    >> Share

  189. ZHANG J, Zhang Z, Liu Y, Hou Y, et al
    Metabolic characteristics of benign and malignant pulmonary nodules and establishment of invasive lung adenocarcinoma model by high-resolution mass spectrometry.
    BMC Cancer. 2025;25:844.
    >> Share

  190. ZHAO F, Bai H, Liu Y, Gao S, et al
    FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma.
    BMC Cancer. 2025;25:831.
    >> Share

  191. DONG J, Qi Y, Sha S, Fu C, et al
    Whole-body CT scanning radiation improves the immune microenvironment of tumor tissues to enhance the antitumor effect of ICI.
    BMC Cancer. 2025;25:824.
    >> Share

  192. HAJIKARIMLOO B, Mohammadzadeh I, Tos SM, Habibi MA, et al
    Machine learning in prediction of epidermal growth factor receptor status in non-small cell lung cancer brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:818.
    >> Share

    April 2025
  193. KUANG S, Xiao S, Zhou J, Liu L, et al
    Combined effect of areca nut, cigarettes, alcohol and SNPs in glycosyltransferase family genes on lung cancer development in Hainan, China.
    BMC Cancer. 2025;25:814.
    >> Share

  194. LIAO J, Hu X, Wei X, Dai W, et al
    Sex-related differences in postoperative patient-reported outcomes among lung cancer patients: a multicenter cohort study.
    BMC Cancer. 2025;25:800.
    >> Share

  195. ZHU Q, Hu H, OuYang LY, Yang R, et al
    The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer.
    BMC Cancer. 2025;25:799.
    >> Share

  196. WANG Y, Ma X, Ma J, Li J, et al
    Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer.
    BMC Cancer. 2025;25:791.
    >> Share

  197. OU G, Gao T, Hu S, Zhang S, et al
    Comprehensive pan-cancer analysis of CHRDL1 and experimental validation of its role in lung adenocarcinoma.
    BMC Cancer. 2025;25:783.
    >> Share

  198. LI S, Huang Z, Zhong X, Zhou Y, et al
    The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database.
    BMC Cancer. 2025;25:767.
    >> Share

  199. MINE H, Sugimoto K, Kobayashi M, Takagi H, et al
    Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma.
    BMC Cancer. 2025;25:764.
    >> Share

  200. DAI L, Huang L, Li L, Tang L, et al
    Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy.
    BMC Cancer. 2025;25:763.
    >> Share

  201. TANG F, Cao XJ, Gong T, Huang XY, et al
    Bronchial arterial chemoembolization/infusion combined with iodine-125 brachytherapy in advanced non-small cell lung cancer: a promising salvage therapy after standard treatment failure.
    BMC Cancer. 2025;25:750.
    >> Share

  202. HOU Y, Xue X, Zhang Z, Mai D, et al
    Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China.
    BMC Cancer. 2025;25:752.
    >> Share

  203. WU S, Guo Y, Wang R
    Combining network pharmacology and experimental verification to explore the inhibitory effects of Deoxyelephantopin (DET) Against Non-Small Cell Lung Cancer (NSCLC).
    BMC Cancer. 2025;25:738.
    >> Share

  204. ZHANG X, Zhang L, Geng Z, Shang M, et al
    Potential profile analysis of financial toxicity and its related factors among lung cancer patients.
    BMC Cancer. 2025;25:740.
    >> Share

  205. HU D, Hu Y, Lei S, Wu D, et al
    MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:732.
    >> Share

  206. LIU C, He Y, Luo J
    The influence of image selection and segmentation on the extraction of lung cancer imaging radiomics features using 3D-Slicer software.
    BMC Cancer. 2025;25:728.
    >> Share

  207. WANG FY, Yeh YC, Lin SY, Wang SY, et al
    Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer.
    BMC Cancer. 2025;25:715.
    >> Share

  208. GAO Y, Hu P, Wu N, Tan F, et al
    A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer.
    BMC Cancer. 2025;25:727.
    >> Share

  209. LIAO S, Sun H, Lu H, Wu J, et al
    Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.
    BMC Cancer. 2025;25:697.
    >> Share

  210. FAN Z, Liu W, Gao Z, Liu Y, et al
    CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.
    BMC Cancer. 2025;25:688.
    >> Share

  211. XU J, Zhang Z, Han K, Yang Z, et al
    EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.
    BMC Cancer. 2025;25:681.
    >> Share

  212. LI Z, Miao H, Bao W, Zhang L, et al
    Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.
    BMC Cancer. 2025;25:692.
    >> Share

  213. KONDO N, Yoshiura T, Kakinohana Y, Yamashita M, et al
    Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2025;25:682.
    >> Share

  214. CAO W, Han S, Zhang P, Mi L, et al
    Immune checkpoint inhibitor-related myocarditis in patients with lung cancer.
    BMC Cancer. 2025;25:685.
    >> Share

  215. LEI Y, Cao C, Tang R, Liu Y, et al
    Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opi
    BMC Cancer. 2025;25:664.
    >> Share

  216. MEI K, Feng Z, Liu H, Wang M, et al
    Preoperative prediction of pulmonary ground-glass nodule infiltration status by CT-based radiomics combined with neural networks.
    BMC Cancer. 2025;25:659.
    >> Share

  217. TAJE R, Gallina FT, Caterino M, Forcella D, et al
    Molecular characterization of early-stage lung adenocarcinoma presenting as subsolid nodules in a real-life European cohort.
    BMC Cancer. 2025;25:647.
    >> Share

  218. LI J, Xu HL, Li WX, Ma XY, et al
    Prognostic factors of survival in patients with lung cancer after low-dose computed tomography screening: a multivariate analysis of a lung cancer screening cohort in China.
    BMC Cancer. 2025;25:646.
    >> Share

  219. XU S, Yin SY, Bie ZX, Li YM, et al
    Personalized drug screening of patient-derived tumor-like cell clusters based on specimens obtained from percutaneous transthoracic needle biopsy in patients with lung malignancy: a real-world study.
    BMC Cancer. 2025;25:649.
    >> Share

  220. SANG H, Liu J, Chen X, Zeng Y, et al
    METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling.
    BMC Cancer. 2025;25:641.
    >> Share

  221. YIN X, Lin X, Zhang G, Yin Y, et al
    Intensity-modulated proton therapy for hippocampal-sparing prophylactic cranial irradiation: a planning comparison with photon therapy.
    BMC Cancer. 2025;25:639.
    >> Share

  222. LI Y, Zhou J, Liu L, Zhu C, et al
    Association of SNPs in nAChRs genes, areca nut chewing and smoking, and their interaction with lung cancer in Hainan, China: a case control study.
    BMC Cancer. 2025;25:626.
    >> Share

  223. CAPDEVILA J, Pubul V, Anido U, Walter T, et al
    A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
    BMC Cancer. 2025;25:613.
    >> Share

  224. GUO RQ, Li YM, Bie ZX, Peng JZ, et al
    Microwave ablation of non-small cell lung cancer enhances local T-cell abundance and alters monocyte interactions.
    BMC Cancer. 2025;25:605.
    >> Share

  225. ZHENG W, Zhou C, Xue Z, Qiao L, et al
    Integrative analysis of a novel signature incorporating metabolism and stemness-related genes for risk stratification and assessing clinical outcomes and therapeutic responses in lung adenocarcinoma.
    BMC Cancer. 2025;25:591.
    >> Share

    March 2025
  226. WU S, Jiang R, Fedorowicz G, Wong M, et al
    Analytical validation of the Percepta Nasal Swab classifier; an RNA next-generation sequencing assay for the assessment of lung cancer risk in pulmonary nodules.
    BMC Cancer. 2025;25:577.
    >> Share

  227. THOMPSON JJ, MacLeod N, Will S, O'Rourke F, et al
    The prognostic value of a laboratory cachexia score (LCAS) defined by LDH, CRP and albumin in patients with advanced lung cancer.
    BMC Cancer. 2025;25:543.
    >> Share

  228. LI S, Du F, Zhang Y, Wang Q, et al
    Myocarditis prediction in locally advanced or metastatic lung cancer patients with cardiac parameters abnormalities undergoing immunotherapy: development and validation of a risk assessment model.
    BMC Cancer. 2025;25:541.
    >> Share

  229. PAN X, Deng H
    Deubiquitinase USP18 mediates cell migration, apoptosis and ferroptosis in lung adenocarcinoma by depending on POU4F1/PRKAA2 axis.
    BMC Cancer. 2025;25:528.
    >> Share

  230. ZHU ZY, Yun YQ, Li H, Qin ZQ, et al
    Subpleural injection of gelatin sponge particles to reduce pneumothorax incidence in CT-guided lung biopsies: a retrospective single-center case-control study.
    BMC Cancer. 2025;25:529.
    >> Share

  231. LIU X, Ji Z, Zhang L, Li L, et al
    Prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer using (18)F-FDG PET radiomics features of primary tumour and lymph nodes.
    BMC Cancer. 2025;25:520.
    >> Share

  232. LIU X, Yin X, Zhuang L, Wen J, et al
    Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study.
    BMC Cancer. 2025;25:509.
    >> Share

  233. CAO L, Li T, Xu X, Sun M, et al
    Texasin, A main product from Caragana Jubata (Pall.) Poir, induces proliferation arrest and protective autophagy in lung adenocarcinoma.
    BMC Cancer. 2025;25:513.
    >> Share

  234. HE D, Lu H, Ou X, Zheng T, et al
    Correction: Exposure to major coronary heart disease events reduces lung cancer risk: a Mendelian randomization study based on a European population.
    BMC Cancer. 2025;25:501.
    >> Share

  235. LIN W, Wang Y, Li M, Feng J, et al
    Tumor treating fields enhance anti-PD therapy by improving CCL2/8 and CXCL9/CXCL10 expression through inducing immunogenic cell death in NSCLC models.
    BMC Cancer. 2025;25:489.
    >> Share

  236. SHI Y, Wang X, Pei Z, Shi H, et al
    Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.
    BMC Cancer. 2025;25:490.
    >> Share

  237. LI Y, Liu Y, Xie Y, Wang Y, et al
    Long-read RNA sequencing enables full-length chimeric transcript annotation of transposable elements in lung adenocarcinoma.
    BMC Cancer. 2025;25:482.
    >> Share

  238. LI Y, Tong Z, Yang Y, Wang Y, et al
    Lung Cancer Biomarker Database (LCBD): a comprehensive and curated repository of lung cancer biomarkers.
    BMC Cancer. 2025;25:478.
    >> Share

  239. ZHAO K, Lu S, Niu J, Zhu H, et al
    Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.
    BMC Cancer. 2025;25:467.
    >> Share

  240. CAI F, Guo Z, Wang G, Luo F, et al
    Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer.
    BMC Cancer. 2025;25:461.
    >> Share

  241. WU T, Cai J, Li Y, Xie R, et al
    Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer.
    BMC Cancer. 2025;25:446.
    >> Share

  242. CAO P, Jia X, Wang X, Fan L, et al
    Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.
    BMC Cancer. 2025;25:443.
    >> Share

  243. WEI K, Sun T, Feng X, Chen Y, et al
    PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study.
    BMC Cancer. 2025;25:444.
    >> Share

  244. JAHANI MM, Mashayekhi P, Omrani MD, Meibody AA, et al
    Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures.
    BMC Cancer. 2025;25:433.
    >> Share

  245. ZHANG Z, Zhao Y, Ma YJ, Chen CQ, et al
    Prediction of STAS in lung adenocarcinoma with nodules
    BMC Cancer. 2025;25:417.
    >> Share

  246. LAI Z, Pang Y, Zhou Y, Chen L, et al
    Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy.
    BMC Cancer. 2025;25:411.
    >> Share

  247. LAI Y, Zhou S, Tian L, Li H, et al
    Preoperative heart rate variability as a predictor of postoperative pneumonia and lung function recovery in surgical lung cancer patients: a prospective observed study.
    BMC Cancer. 2025;25:404.
    >> Share

  248. ZHANG L, Luo J, Wu X
    Impact of single-port versus three-port video-assisted thoracic surgery lobectomy on postoperative pain and quality of life in early-stage non-small cell lung cancer patients: a meta-analysis.
    BMC Cancer. 2025;25:400.
    >> Share

  249. NIE X, Zou M, Song C, Zhang P, et al
    Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients.
    BMC Cancer. 2025;25:393.
    >> Share

  250. SHIMA Y, Yoshida H, Suminaga K, Yoshida H, et al
    Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.
    BMC Cancer. 2025;25:388.
    >> Share

  251. ZHI L, Zhang Z, Gao Q, Shang C, et al
    Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
    BMC Cancer. 2025;25:386.
    >> Share

    February 2025
  252. OH JH, Lee SJ, Park YJ
    F-18 FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell lung cancer.
    BMC Cancer. 2025;25:379.
    >> Share

  253. HUANG F, Lin X, Hong Y, Li Y, et al
    The feasibility and cost-effectiveness of implementing mobile low-dose computed tomography with an AI-based diagnostic system in underserved populations.
    BMC Cancer. 2025;25:345.
    >> Share

  254. ZHI L, Zhang Z, Gao Q, Shang C, et al
    CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
    BMC Cancer. 2025;25:337.
    >> Share

  255. GAO H, Zou X, Fan M, Chen M, et al
    Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion.
    BMC Cancer. 2025;25:350.
    >> Share

  256. IEMWIMANGSA N, Anantaya D, Oranratnachai S, Thamrongjirapat T, et al
    Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy.
    BMC Cancer. 2025;25:333.
    >> Share

  257. BAO T, Deng Y, Chen L, Sun W, et al
    Primary tumour resection in non-small cell lung cancer patients with pleural dissemination unexpectedly detected during operation: a two-centre retrospective cohort study.
    BMC Cancer. 2025;25:316.
    >> Share

  258. HUANG Z, Wang H, Ting F, Chen Y, et al
    Metabolic and multi-model intravoxel incoherent motion parameters based (18)F-FDG PET/MRI for predicting subtypes of inoperable non-small cell lung cancer.
    BMC Cancer. 2025;25:322.
    >> Share

  259. YANG Y, Li X, Duan Y, Zhao J, et al
    Risk factors for malignant solid pulmonary nodules: a meta-analysis.
    BMC Cancer. 2025;25:312.
    >> Share

  260. WANG X, Wu YX, Hu WP, Zhang J, et al
    Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy.
    BMC Cancer. 2025;25:307.
    >> Share

  261. CHEN W, Gao P, Lu F, Wang E, et al
    CT texture features of lung adenocarcinoma with HER2 mutation.
    BMC Cancer. 2025;25:287.
    >> Share

  262. FUKUSHIMA T, Katsushima U, Ogushi N, Hase K, et al
    Lower-extremity muscle strength is associated with prognosis in patients with advanced or recurrent lung cancer: a retrospective, observational study.
    BMC Cancer. 2025;25:282.
    >> Share

  263. XINJING Z, Lei G, Xinbao L, Zhonghe J, et al
    Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    BMC Cancer. 2025;25:270.
    >> Share

  264. WANG H, Chen K, Ma S, Huang W, et al
    PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer.
    BMC Cancer. 2025;25:263.
    >> Share

  265. YANG X, Song Y, Xu R, Yang Y, et al
    Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers after complete resection: a retrospective real-world study.
    BMC Cancer. 2025;25:266.
    >> Share

  266. DU CC, Sun DQ, Chen YX, Li JS, et al
    Study of the microenvironment of the lung flora in female lung adenocarcinoma patients: from benign lesions to invasive lung adenocarcinomas.
    BMC Cancer. 2025;25:252.
    >> Share

  267. ZHANG P, Wang L, Liu H, Lin S, et al
    Unveiling the crucial role of glycosylation modification in lung adenocarcinoma metastasis through artificial neural network-based spatial multi-omics single-cell analysis and Mendelian randomization.
    BMC Cancer. 2025;25:249.
    >> Share

  268. WU D, Huang Y, Wang B, Zheng Q, et al
    A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer.
    BMC Cancer. 2025;25:236.
    >> Share

  269. JIANG Y, Hu X, Heibi Y, Wu H, et al
    Exploring prognostic precision: a nomogram approach for malignant pleural effusion in lung cancer.
    BMC Cancer. 2025;25:227.
    >> Share

  270. CHEN H, Xu Y, Chen D, Xiao D, et al
    The Hippo pathway promotes platinum-based chemotherapy by inhibiting MTF1-dependent heavy metal response.
    BMC Cancer. 2025;25:223.
    >> Share

  271. GAO R, Liang W, Chen J, Yang M, et al
    Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system.
    BMC Cancer. 2025;25:216.
    >> Share

  272. KRAFT A, Kirschner MB, Orlowski V, Ronner M, et al
    Exploring RNA cargo in extracellular vesicles for pleural mesothelioma detection.
    BMC Cancer. 2025;25:212.
    >> Share

  273. QU J, Chen Z, Zhu Y, Huang J, et al
    Pulmonary Nuclear protein in Testis (NUT) carcinoma: clinical, molecular characteristics, and treatment strategies.
    BMC Cancer. 2025;25:196.
    >> Share

    January 2025
  274. ZHANG D, Liu G, Ye J, Li K, et al
    Low-exhaustion peripheral circulating gammadelta T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study.
    BMC Cancer. 2025;25:178.
    >> Share

  275. LUO L, Ji J, Dong J, He M, et al
    Infiltration and subtype analysis of CD3 + CD20 + T cells in lung cancer.
    BMC Cancer. 2025;25:179.
    >> Share

  276. HE D, Lu H, Ou X, Zheng T, et al
    Exposure to major coronary heart disease events reduces lung cancer risk: a mendelian randomization study based on a European population.
    BMC Cancer. 2025;25:152.
    >> Share

  277. TANG C, Sun SX, Gu C, Li CJ, et al
    Diagnostic and prognostic values of tsRNAs in lung cancer: a meta-analysis.
    BMC Cancer. 2025;25:153.
    >> Share

  278. KUNCMAN L, Fijuth J, Tworek D, Sierko E, et al
    Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial.
    BMC Cancer. 2025;25:142.
    >> Share

  279. ZHOU Y, Zhao L, Cai M, Luo D, et al
    Utilizing sc-linker to integrate single-cell RNA sequencing and human genetics to identify cell types and driver genes associated with non-small cell lung cancer.
    BMC Cancer. 2025;25:130.
    >> Share

  280. NI R, Huang Y, Wang L, Chen H, et al
    An early lung cancer diagnosis model for non-smokers incorporating ct imaging analysis and circulating genetically abnormal cells (CACs).
    BMC Cancer. 2025;25:124.
    >> Share

  281. MA J, Xu X, Huang W, Hu Y, et al
    Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers.
    BMC Cancer. 2025;25:118.
    >> Share

  282. YANG H, Li MH, Li QH, Cheng KB, et al
    Clinical analysis of pulmonary mucosa-associated lymphoid tissue lymphoma coexisting with lung cancer.
    BMC Cancer. 2025;25:120.
    >> Share

  283. SHIGENOBU T, Taniguchi Y, Suzuki T, Tabuchi Y, et al
    Surgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching.
    BMC Cancer. 2025;25:121.
    >> Share

  284. CHEN S, Wu S
    Ensemble machine learning models for lung cancer incidence risk prediction in the elderly: a retrospective longitudinal study.
    BMC Cancer. 2025;25:126.
    >> Share

  285. LIAO R, Yi G, Shen L, Xiao X, et al
    Characterization of the genomic landscape in liver oligometastatic NSCLC.
    BMC Cancer. 2025;25:93.
    >> Share

  286. LIU X, Lv W, Huang D, Cui H, et al
    The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:87.
    >> Share

  287. ZHANG F, Qi F, Han Y, Yang H, et al
    Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.
    BMC Cancer. 2025;25:89.
    >> Share

  288. YANG M, Zheng G, Chen F, Tang H, et al
    Molecular characterization of EBV-associated primary pulmonary lymphoepithelial carcinoma by multiomics analysis.
    BMC Cancer. 2025;25:85.
    >> Share

  289. YIN W, Lin Z, Gong WJ, Wang WX, et al
    Smoking cessation is a protective factor for lung cancer onset and mortality: a population-based prospective cohort study.
    BMC Cancer. 2025;25:86.
    >> Share

  290. YING S, Wu N, Ruan Y, Ge W, et al
    IL-17 triggers PD-L1 gene transcription in NSCLC cells via TRIM31-dependent MEF2C K63-linked polyubiquitination.
    BMC Cancer. 2025;25:81.
    >> Share

  291. LUAN Y, Liang C, Han Q, Zhou X, et al
    The systematic analysis of genes related to butyrate metabolism suggests that CDKN3 could serve as a promising therapeutic target for lung adenocarcinoma treatment.
    BMC Cancer. 2025;25:69.
    >> Share

  292. WANG Z, Cui W, Liang L, Qu J, et al
    Exploring the role of ELOVLs family in lung adenocarcinoma based on bioinformatic analysis and experimental validation.
    BMC Cancer. 2025;25:62.
    >> Share

  293. ZUO Z, Deng J, Ge W, Zhou Y, et al
    Quantifying intratumoral heterogeneity within sub-regions to predict high-grade patterns in clinical stage I solid lung adenocarcinoma.
    BMC Cancer. 2025;25:51.
    >> Share

  294. ZHANG R, Jiang Y, Gu J, Zhang X, et al
    Diagnostic role of circulating long non-coding RNA LINC00312 in patients with non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2025;25:47.
    >> Share

  295. ZHAO Y, Zhou C, Zuo L, Yan H, et al
    Identification of cancer cell-intrinsic biomarkers associated with tumor progression and characterization of SFTA3 as a tumor suppressor in lung adenocarcinomas.
    BMC Cancer. 2025;25:36.
    >> Share

  296. LISHCHUK P, Kuznietsova H, Dovbynchuk T, Dziubenko N, et al
    Impact of irradiation conditions on therapy of Lewis lung carcinoma in mice using glucose-ethylenediamine carbon dots.
    BMC Cancer. 2025;25:39.
    >> Share

  297. EVERATT R, Kuzmickiene I, Brasiuniene B, Vincerzevskiene I, et al
    Postdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
    BMC Cancer. 2025;25:38.
    >> Share

  298. XIONG Y, Ma Y, Lei J, Zhu J, et al
    Highly proliferating cancer cells function as novel prognostic biomarkers for lung adenocarcinoma with particular usefulness for stage IA risk stratification.
    BMC Cancer. 2025;25:25.
    >> Share

  299. HAMAKAWA Y, Hirahara A, Hayashi A, Ito K, et al
    Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.
    BMC Cancer. 2025;25:17.
    >> Share

  300. ZHU L, Liu J, Huang X, Hu J, et al
    Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I-IIIB small-cell lung cancer.
    BMC Cancer. 2025;25:8.
    >> Share

  301. GONG W, Vaishnani DK, Jin XC, Zeng J, et al
    Evaluation of an enhanced ResNet-18 classification model for rapid On-site diagnosis in respiratory cytology.
    BMC Cancer. 2025;25:10.
    >> Share

  302. LIAN Z, Liu X, Li X
    Elucidating the expression and role of cGAS in pan-cancer using integrated bioinformatics and experimental approaches.
    BMC Cancer. 2025;25:5.
    >> Share

    December 2024
  303. LUAN T, Hao J, Gu Y, He P, et al
    A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.
    BMC Cancer. 2024;24:1597.
    >> Share

  304. BORILOVA S, Grell P, Selingerova I, Gescheidtova L, et al
    Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer.
    BMC Cancer. 2024;24:1590.
    >> Share

  305. WANG B, Zhang J, Shi Y, Wang Y, et al
    Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.
    BMC Cancer. 2024;24:1574.
    >> Share

  306. DENG G, Zhang Q, Fan J, Zhao C, et al
    Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases.
    BMC Cancer. 2024;24:1571.
    >> Share

  307. LIU Y, Geng Q, Lin X, Feng C, et al
    Benefits, harms, and cost-effectiveness of risk model-based and risk factor-based low-dose computed tomography screening strategies for lung cancer: a systematic review.
    BMC Cancer. 2024;24:1567.
    >> Share

  308. MA F, Zheng W, Wang W, Zhang N, et al
    The mediating role of medical coping modes between stigma and quality of life in patients undergoing lung cancer surgery: a cross-sectional study.
    BMC Cancer. 2024;24:1561.
    >> Share

  309. LOCQUET M, Jacob S, Geets X, Beaudart C, et al
    Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1556.
    >> Share

  310. XIE X, Li Y, Lv Q, Wang W, et al
    Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy.
    BMC Cancer. 2024;24:1541.
    >> Share

  311. JIANG D, Wang Z, Li H, Liu J, et al
    Experiences of patient delay among lung cancer patients in South China.
    BMC Cancer. 2024;24:1527.
    >> Share

  312. ZHANG W, Dai T, Wang D, Zhu Y, et al
    Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials.
    BMC Cancer. 2024;24:1522.
    >> Share

  313. ZHANG Y, Zeng Y, Yin Y, Zhang W, et al
    The role of radiotherapy in extensive-stage small cell lung cancer: insights from treatment failure patterns in the era of immunotherapy.
    BMC Cancer. 2024;24:1534.
    >> Share

  314. MOU K, Wang H, Zhu S, Luo J, et al
    Comprehensive analysis of the prognostic and immunological role of cavins in non-small cell lung cancer.
    BMC Cancer. 2024;24:1525.
    >> Share

  315. SONG J, Ye X, Peng Q, Ying X, et al
    Correction: Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer.
    BMC Cancer. 2024;24:1511.
    >> Share

  316. ZHENG X, Liu K, Gao Z, Li C, et al
    Predicting overall survival and prophylactic cranial irradiation benefit in small cell lung cancer patients: a multicenter cohort study.
    BMC Cancer. 2024;24:1507.
    >> Share

  317. CHEN Q, Li Y, Lin Y, Lin X, et al
    Effectiveness of non-pharmacological interventions in managing symptom clusters among lung cancer patients: a systematic review.
    BMC Cancer. 2024;24:1505.
    >> Share

  318. ZHANG X, Sun Q, Chen R, Zhao M, et al
    Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study.
    BMC Cancer. 2024;24:1492.
    >> Share

  319. SONG J, Ye X, Peng Q, Ying X, et al
    Circulating Tumor cells and multiple indicators combined to identify the risk of poorer prognosis in patients with resected non-small cell lung cancer.
    BMC Cancer. 2024;24:1491.
    >> Share

    November 2024
  320. SON JW, Lee J, Jeon JH, Cho S, et al
    Validation of IASLC 9th edition TNM classification for lung cancer: focus on N descriptor.
    BMC Cancer. 2024;24:1460.
    >> Share

  321. DEHGHANI F, Toorang F, Seyyedsalehi MS, Sasanfar B, et al
    Association between the dietary inflammatory index and risk of lung cancer: a multi-centered case-control study.
    BMC Cancer. 2024;24:1452.
    >> Share

  322. LEI S, Tian L, Yang L, Yang Y, et al
    Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.
    BMC Cancer. 2024;24:1427.
    >> Share

  323. KOYAMA J, Morise M, Furukawa T, Oyama S, et al
    Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer.
    BMC Cancer. 2024;24:1417.
    >> Share

  324. RASMUSSEN TR, Gouliaev A, Jakobsen E, Hjorthaug K, et al
    Impact of multidisciplinary team discrepancies on comparative lung cancer outcome analyses and treatment equality.
    BMC Cancer. 2024;24:1423.
    >> Share

  325. BADE BC, Gan G, Li F, Lu L, et al
    Correction: Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study.
    BMC Cancer. 2024;24:1409.
    >> Share

  326. ZHANG X, Meng J, Gao M, Gong C, et al
    Identifying immunohistochemical biomarkers panel for non-small cell lung cancer in optimizing treatment and forecasting efficacy.
    BMC Cancer. 2024;24:1397.
    >> Share

  327. LIU A, Wang X, Wang L, Zhuang H, et al
    EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis.
    BMC Cancer. 2024;24:1390.
    >> Share

  328. LI Y, Shi D, Jiang Y, Hu Y, et al
    Establishment of potential lncRNA-related hub genes involved competitive endogenous RNA in lung adenocarcinoma.
    BMC Cancer. 2024;24:1371.
    >> Share

  329. MAO Y, Chen F, Ye Z, Li Z, et al
    Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis.
    BMC Cancer. 2024;24:1366.
    >> Share

  330. ZHANG Y, Li J, Song X, Zhao F, et al
    Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy.
    BMC Cancer. 2024;24:1368.
    >> Share

  331. CHEN Z, Yi G, Li X, Yi B, et al
    Predicting radiation pneumonitis in lung cancer using machine learning and multimodal features: a systematic review and meta-analysis of diagnostic accuracy.
    BMC Cancer. 2024;24:1355.
    >> Share

  332. ZAFAR A, Rashid AA, Moeed A, Tahir MJ, et al
    Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1353.
    >> Share

  333. JI Y, Harris MA, Newton LM, Harris TJ, et al
    Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.
    BMC Cancer. 2024;24:1350.
    >> Share

  334. TANG J, Wang T, Wu H, Bao X, et al
    Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis.
    BMC Cancer. 2024;24:1351.
    >> Share

    October 2024
  335. WANG T, Li R, Liu S, Wu Q, et al
    The effects of immune checkpoint inhibitors vs. chemotherapy combined with brain radiotherapy in non-small cell lung cancer patients with brain metastases.
    BMC Cancer. 2024;24:1343.
    >> Share

  336. SESTER S, Wilms G, Ahlburg J, Babendreyer A, et al
    Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.
    BMC Cancer. 2024;24:1341.
    >> Share

  337. XIONG Y, Wang L, Zhang W, Meng Y, et al
    First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.
    BMC Cancer. 2024;24:1326.
    >> Share

  338. WU DN, Zhang KL, Chen RH, Ye WS, et al
    VASN promotes the aggressive phenotype in ARID1A-deficient lung adenocarcinoma.
    BMC Cancer. 2024;24:1327.
    >> Share

  339. TANG Y, Zhao S, Zhou L, Huang Y, et al
    A 16-year evaluation of opportunistic lung cancer screening with low-dose CT in China: comparative findings between non-smokers and smokers.
    BMC Cancer. 2024;24:1322.
    >> Share

  340. SHEN F, Wu X, Geng J, Guo W, et al
    Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1317.
    >> Share

  341. SANTORO A, Pilar G, Tan DSW, Zugazagoitia J, et al
    Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
    BMC Cancer. 2024;24:1307.
    >> Share

  342. TONG Y, Wan X, Yin C, Lei T, et al
    In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.
    BMC Cancer. 2024;24:1305.
    >> Share

  343. MENG F, Ren N, Zhang G, Xu R, et al
    Comprehensive analysis of surgical strategies and prognosis for non-small cell lung cancer with pleural metastasis detected intraoperatively.
    BMC Cancer. 2024;24:1303.
    >> Share

  344. SAITO Y, Takekuma Y, Sakakibara-Konishi J, Shimizu Y, et al
    Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment.
    BMC Cancer. 2024;24:1301.
    >> Share

  345. SUGAI K, Mori T, Bilal T, Furukawa A, et al
    Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study.
    BMC Cancer. 2024;24:1291.
    >> Share

  346. WANG F, Liu J, Liao W, Zheng L, et al
    Matrine alkaloids modulating DNA damage repair in chemoresistant non-small cell lung cancer cells.
    BMC Cancer. 2024;24:1283.
    >> Share

  347. YU Q, Yang H, Xiao F, Wang Z, et al
    Network meta-analysis on the efficacy and safety of management for resectable stage IIIA-N2 non-small cell lung cancer.
    BMC Cancer. 2024;24:1286.
    >> Share

  348. DING D, Shang W, Shi K, Ying J, et al
    FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis.
    BMC Cancer. 2024;24:1270.
    >> Share

  349. HEMEAD H, Aly RG, Kotb M, Abdelaziz A, et al
    Pediatric pleuropulmonary blastoma: analysis of four cases.
    BMC Cancer. 2024;24:1268.
    >> Share

  350. HOU Q, Liang Y, Yao N, Liu J, et al
    Development of a novel nomogram for patients with SCLC and comparison with other models.
    BMC Cancer. 2024;24:1257.
    >> Share

  351. SHEN Z, Huang Z, Zhu T, Zhang J, et al
    Optimal surgical timing for lung cancer following SARS-CoV-2 infection: a prospective multicenter cohort study.
    BMC Cancer. 2024;24:1250.
    >> Share

  352. CHENG H, Wang X, Yao J, Guo N, et al
    Assessing the causal relationship between non-small cell lung cancer and sepsis: a Mendelian randomization study.
    BMC Cancer. 2024;24:1233.
    >> Share

  353. ZHANG L, Wang S, Wang L
    Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma.
    BMC Cancer. 2024;24:1235.
    >> Share

  354. WU D, Li Y, Zhou M, Gong F, et al
    Deep learning-based characterization of pathological subtypes in lung invasive adenocarcinoma utilizing (18)F-deoxyglucose positron emission tomography imaging.
    BMC Cancer. 2024;24:1229.
    >> Share

  355. ZHU X, Shen C, Dong J
    A clinically applicable model more suitable for predicting malignancy or benignity of pulmonary ground glass nodules in women patients.
    BMC Cancer. 2024;24:1225.
    >> Share

  356. YILMAZ F, Yasar S, Tatar OD, Yildirim HC, et al
    Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.
    BMC Cancer. 2024;24:1218.
    >> Share

    September 2024
  357. SUN M, Ji H, Deng F, Li J, et al
    Clinical outcomes and synergistic effect between radiotherapy and immunotherapy in patients with extensive-stage small cell lung cancer: a real-world study.
    BMC Cancer. 2024;24:1206.
    >> Share

  358. BOZCUK HS, Artac M
    A simulated trial with reinforcement learning for the efficacy of Irinotecan and Ifosfamide versus Topotecan in relapsed, extensive stage small cell lung cancer.
    BMC Cancer. 2024;24:1207.
    >> Share

  359. DING W, Xu T, Xiang H, Liang J, et al
    Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.
    BMC Cancer. 2024;24:1198.
    >> Share

  360. LI H, Fu X, Liu M, Chen J, et al
    Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.
    BMC Cancer. 2024;24:1178.
    >> Share

  361. WANG W, Wu G, Luo W, Lin L, et al
    Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.
    BMC Cancer. 2024;24:1182.
    >> Share

  362. DENG JY, Yang MY, Yang XR, Chen ZH, et al
    Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2024;24:1190.
    >> Share

  363. TOORANG F, Seyyedsalehi MS, Sasanfar B, Rashidian H, et al
    Dietary total antioxidant capacity and odds of lung cancer: a large case-control study.
    BMC Cancer. 2024;24:1196.
    >> Share

  364. HUSSEIN NA, Ebied SA, Belal AAM, Ahmad MA, et al
    Expression profiling of circulating lncRNA GIAT4RA, lncRNA AATBC, lncRNA Sirt1-AS, and SMARCB1 in lung cancer patients.
    BMC Cancer. 2024;24:1175.
    >> Share

  365. DENG Y, Chen X, Chen X, Huang C, et al
    UBE2T promotes stage I lung adenocarcinoma progression through PBX1 ubiquitination and PBX1/RORA regulation.
    BMC Cancer. 2024;24:1158.
    >> Share

  366. XU S, Chen X, Ying H, Chen J, et al
    Multi?omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma.
    BMC Cancer. 2024;24:1138.
    >> Share

  367. CUI J, An Z, Zhou X, Zhang X, et al
    Prognosis and risk factor assessment of patients with advanced lung cancer with low socioeconomic status: model development and validation.
    BMC Cancer. 2024;24:1128.
    >> Share

  368. LIU R, Wang J, Zhang L, Wang S, et al
    GLIDR-mediated regulation of tumor malignancy and cisplatin resistance in non-small cell lung cancer via the miR-342-5p/PPARGC1A axis.
    BMC Cancer. 2024;24:1126.
    >> Share

  369. RUCO A, Lofters AK, Lu H, Baxter NN, et al
    Lung cancer survival by immigrant status: a population-based retrospective cohort study in Ontario, Canada.
    BMC Cancer. 2024;24:1114.
    >> Share

  370. HAGHIGHIKIAN SM, Shirinzadeh-Dastgiri A, Ershadi R, Vakili-Ojarood M, et al
    Correlation of TNF-alpha polymorphisms with susceptibility to lung cancer: evidence from a meta-analysis based on 29 studies.
    BMC Cancer. 2024;24:1113.
    >> Share

  371. WANG W, Zhang X, Gui P, Zou Q, et al
    SEPT9: From pan-cancer to lung squamous cell carcinoma.
    BMC Cancer. 2024;24:1105.
    >> Share

  372. YANG D, Yang Y, Zhao M, Ji H, et al
    Evaluation of the invasiveness of pure ground-glass nodules based on dual-head ResNet technique.
    BMC Cancer. 2024;24:1080.
    >> Share

  373. BEFFA ED, Lyberis P, Rosboch GL, Arezzo A, et al
    Study protocol for Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (phase II Trial) - (the RECOGNISE study).
    BMC Cancer. 2024;24:1078.
    >> Share

    August 2024
  374. XU S, Zheng Y, Ye M, Shen T, et al
    Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response.
    BMC Cancer. 2024;24:1064.
    >> Share

  375. LI Q, Liang N, Ouyang W, Su S, et al
    Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs.
    BMC Cancer. 2024;24:1053.
    >> Share

  376. SHI Y, Xu Y, Wang M
    Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation.
    BMC Cancer. 2024;24:1043.
    >> Share

  377. HOSOYA K, Ozasa H, Tanji M, Yoshida H, et al
    Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.
    BMC Cancer. 2024;24:1030.
    >> Share

  378. LUO LL, Cao Y, Zhang JJ, Xie YX, et al
    The role of tRF-Val-CAC-010 in lung adenocarcinoma: implications for tumorigenesis and metastasis.
    BMC Cancer. 2024;24:1033.
    >> Share

  379. WU W, Yu S, Huang J, Qi Q, et al
    Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study.
    BMC Cancer. 2024;24:1010.
    >> Share

  380. SHAN H, Wang X, Yin F, Zhou Y, et al
    Combination of transcriptome and Mendelian inheritance reveals novel prognostic biomarker of CTLA-4-related lncRNAs and protective role of nitrogen metabolism pathway in lung adenocarcinoma development.
    BMC Cancer. 2024;24:1009.
    >> Share

  381. PARK JO, Feng YH, Su WC, Oh DY, et al
    Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial.
    BMC Cancer. 2024;24:1006.
    >> Share

  382. AHSAN S, Win TT, Aye SN, Than NN, et al
    The role of circular RNAs (circRNAs) as a prognostic factor in lung cancer: a meta-analysis.
    BMC Cancer. 2024;24:988.
    >> Share

  383. SUN V, Guthrie KA, Arnold KB, Antonoff M, et al
    Comparative effectiveness of perioperative physical activity in older adults with lung cancer and their family caregivers: design of a multicenter pragmatic randomized trial.
    BMC Cancer. 2024;24:976.
    >> Share

  384. MA Z, Liu Y, Bao Y, Liu Q, et al
    Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy.
    BMC Cancer. 2024;24:968.
    >> Share

  385. ZHANG J, Lv PY, Zhao X, Liu ML, et al
    Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
    BMC Cancer. 2024;24:967.
    >> Share

  386. KENNEDY K, Jusue-Torres I, Buller ID, Rossi E, et al
    Neighborhood-level deprivation and survival in lung cancer.
    BMC Cancer. 2024;24:959.
    >> Share

  387. AKDOGAN O, Ogut B, Sutcuoglu O, Sert A, et al
    The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer.
    BMC Cancer. 2024;24:954.
    >> Share

  388. YAO N, Qin Z, Chen M, Hu L, et al
    Effects of brain radiotherapy strategies on survival in the era of MRI for patients with limited stage small cell lung cancer.
    BMC Cancer. 2024;24:953.
    >> Share

  389. GARRIDO J, Bernal Y, Gonzalez E, Blanco A, et al
    Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
    BMC Cancer. 2024;24:951.
    >> Share

  390. QIN H, Yan H, Chen Y, Xu Q, et al
    Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    BMC Cancer. 2024;24:952.
    >> Share

  391. LAHMADI M, Beddar L, Ketit S, Makhbouche T, et al
    Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study.
    BMC Cancer. 2024;24:946.
    >> Share

  392. DENG H, Wang L, Li Z, Zhan T, et al
    Optimal treatment strategies for hepatoid adenocarcinoma of the lung: insights from a comprehensive analysis.
    BMC Cancer. 2024;24:948.
    >> Share

  393. MCINNERNEY D, Quaife SL, Cooke S, Mitchinson L, et al
    Understanding the impact of distance and disadvantage on lung cancer care and outcomes: a study protocol.
    BMC Cancer. 2024;24:942.
    >> Share

  394. CHEN F, Ren P, Xu R, Zhang J, et al
    FAM65A promotes the progression and growth of lung squamous cell carcinoma in vivo and vitro.
    BMC Cancer. 2024;24:944.
    >> Share

  395. KASEDA K, Asakura K, Shintani Y, Okami J, et al
    Surgically resected sarcomatoid carcinoma of the lung: a nationwide retrospective study in 2010.
    BMC Cancer. 2024;24:938.
    >> Share

  396. FRAK M, Grenda A, Krawczyk P, Kuznar-Kaminska B, et al
    The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients.
    BMC Cancer. 2024;24:937.
    >> Share

    July 2024
  397. GE QY, Zheng C, Zhang GC, Cong ZZ, et al
    Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma.
    BMC Cancer. 2024;24:925.
    >> Share

  398. LI Z, Wang J, Deng L, Zhai Y, et al
    Hippocampal avoidance whole-brain radiotherapy with simultaneous integrated boost in lung cancer brain metastases and utility of the Hopkins verbal learning test for testing cognitive impairment in Chinese patients: a prospective phase II study.
    BMC Cancer. 2024;24:899.
    >> Share

  399. TOKITO T, Kolesnik O, Sorensen J, Artac M, et al
    Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.
    BMC Cancer. 2024;23.
    >> Share

  400. BOYER M, Hui R, Urban D, Clingan P, et al
    Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
    BMC Cancer. 2024;23.
    >> Share

  401. WEN Y, Wu W, Liufu Y, Pan X, et al
    Differentiation of granulomatous nodules with lobulation and spiculation signs from solid lung adenocarcinomas using a CT deep learning model.
    BMC Cancer. 2024;24:875.
    >> Share

  402. YAN W, Yang H, Duan D, Wu Y, et al
    Bone marrow mesenchymal stem cells-derived exosomal miR-145-5p reduced non-small cell lung cancer cell progression by targeting SOX9.
    BMC Cancer. 2024;24:883.
    >> Share

  403. HUI W, Gao Z, Zhu M, Wu H, et al
    Reply to "Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach".
    BMC Cancer. 2024;24:881.
    >> Share

  404. LEARY A, Estevez-Garcia P, Sabatier R, Ray-Coquard I, et al
    ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
    BMC Cancer. 2024;24:876.
    >> Share

  405. BULLEMENT A, Edmondson-Jones M, Latimer N
    Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach.
    BMC Cancer. 2024;24:879.
    >> Share

  406. WANG Y, Chen R, Guo Z, Wei W, et al
    Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer.
    BMC Cancer. 2024;24:851.
    >> Share

  407. WU G, Liu J, Shi H, Pan B, et al
    The associations between dysregulation of human blood metabolites and lung cancer risk: evidence from genetic data.
    BMC Cancer. 2024;24:854.
    >> Share

  408. CHEN Y, Wu S, Han Y, Shi H, et al
    LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation.
    BMC Cancer. 2024;24:848.
    >> Share

  409. YAMAGUCHI T, Shimizu J, Matsuzawa R, Watanabe N, et al
    Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    BMC Cancer. 2024;24:842.
    >> Share

  410. BIAN Y, Liu H, Huang J, Feng Z, et al
    eHSP90alpha in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma.
    BMC Cancer. 2024;24:835.
    >> Share

  411. MA L, Li R, Liu X, Yu W, et al
    Prognostic and clinicopathological significance of tertiary lymphoid structure in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:815.
    >> Share

  412. LIN P, Zhang L, Tang X, Wang J, et al
    Exploring the causal association between uric acid and lung cancer in east Asian and European populations: a mendelian randomization study.
    BMC Cancer. 2024;24:801.
    >> Share

  413. YAN L, Su H, Liu J, Wen X, et al
    Rapid detection of lung cancer based on serum Raman spectroscopy and a support vector machine: a case-control study.
    BMC Cancer. 2024;24:791.
    >> Share

    June 2024
  414. CHENG Y, Zhang C, Li Q, Yang X, et al
    MTF1 genetic variants are associated with lung cancer risk in the Chinese Han population.
    BMC Cancer. 2024;24:778.
    >> Share

  415. FAN X, Zhong R, Liang H, Zhong Q, et al
    Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis.
    BMC Cancer. 2024;24:775.
    >> Share

  416. XIAO X, Sun Z, Liang S, Li W, et al
    Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.
    BMC Cancer. 2024;24:749.
    >> Share

  417. ZHANG B, Liu H, Shi C, Gao Z, et al
    Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    BMC Cancer. 2024;24:715.
    >> Share

  418. SONG L, Wu D, Wu J, Zhang J, et al
    Investigating causal associations between pneumonia and lung cancer using a bidirectional mendelian randomization framework.
    BMC Cancer. 2024;24:721.
    >> Share

  419. HUI W, Li W, Song R, Xin Y, et al
    Time-dependent efficacy analysis of first-line immunotherapies for advanced non-small cell lung cancer.
    BMC Cancer. 2024;24:684.
    >> Share

  420. LIU Y, Huang J, Chen JC, Chen W, et al
    Predicting treatment response in multicenter non-small cell lung cancer patients based on federated learning.
    BMC Cancer. 2024;24:688.
    >> Share

  421. BIYU H, Mengshan L, Yuxin H, Ming Z, et al
    A miRNA-disease association prediction model based on tree-path global feature extraction and fully connected artificial neural network with multi-head self-attention mechanism.
    BMC Cancer. 2024;24:683.
    >> Share

  422. ZHAO J, Lu Y, Ren X, Bian T, et al
    Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
    BMC Cancer. 2024;24:687.
    >> Share

  423. SONG W, Li Y, Yao Y, Sun S, et al
    Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer.
    BMC Cancer. 2024;24:680.
    >> Share

  424. YANG L, Jiang Z, Tong J, Li N, et al
    Development and validation of a preoperative CT?based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study.
    BMC Cancer. 2024;24:670.
    >> Share

    May 2024
  425. LU F, Wang E, Liu H
    Factors correlating the expression of PD-L1.
    BMC Cancer. 2024;24:642.
    >> Share

  426. ZHAO W, Liu Y, Yang Y, Wang L, et al
    New link between RNH1 and E2F1: regulates the development of lung adenocarcinoma.
    BMC Cancer. 2024;24:635.
    >> Share

  427. HAYASHI Y, Ueyama A, Funaki S, Jinushi K, et al
    In situ analysis of CCR8(+) regulatory T cells in lung cancer: suppression of GzmB(+) CD8(+) T cells and prognostic marker implications.
    BMC Cancer. 2024;24:627.
    >> Share

  428. LI W, Wu J, Jia Q, Shi Y, et al
    PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
    BMC Cancer. 2024;24:633.
    >> Share

  429. LIN X, Wang F, Li Y, Lei F, et al
    Exploring shared decision-making needs in lung cancer screening among high-risk groups and health care providers in China: a qualitative study.
    BMC Cancer. 2024;24:613.
    >> Share

  430. PRETE M, Ballarin G, Porciello G, Arianna A, et al
    Bioelectrical impedance analysis-derived phase angle (PhA) in lung cancer patients: a systematic review.
    BMC Cancer. 2024;24:608.
    >> Share

  431. LIAO S, Wang Y, Zhou J, Liu Y, et al
    Associations between chronic obstructive pulmonary disease and ten common cancers: novel insights from Mendelian randomization analyses.
    BMC Cancer. 2024;24:601.
    >> Share

  432. PANG H, Dai L, Chen L, Chen X, et al
    Prognostic value of the advanced lung cancer inflammation index in patients with gastric cancer after radical gastrectomy: a propensity-score matching cohort study and meta-analysis.
    BMC Cancer. 2024;24:583.
    >> Share

  433. GU C, Teng X, Sun X, Liu J, et al
    Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma.
    BMC Cancer. 2024;24:585.
    >> Share

  434. WANG M, Jing X, Chen F, Lu S, et al
    Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer.
    BMC Cancer. 2024;24:569.
    >> Share

  435. XIA L, Lin H, Cao H, Lian J, et al
    Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma.
    BMC Cancer. 2024;24:561.
    >> Share

    April 2024
  436. CUNNINGHAM R, Stanley J, Imlach F, Haitana T, et al
    Cancer diagnosis after emergency presentations in people with mental health and substance use conditions: a national cohort study.
    BMC Cancer. 2024;24:546.
    >> Share

  437. VIANA VELOSO GG, Amaral FD, Nogueira-Rodrigues A
    Impact of COVID-19 pandemic among patients with lung and head and neck cancer assisted in a public cancer center in Brazil.
    BMC Cancer. 2024;24:539.
    >> Share

  438. DENG Z, Liu X, Wu R, Yan H, et al
    Ultrasound-based radiomics machine learning models for diagnosing cervical lymph node metastasis in patients with non-small cell lung cancer: a multicentre study.
    BMC Cancer. 2024;24:536.
    >> Share

  439. LI Y, Gong B, Guo Y, Liu W, et al
    Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
    BMC Cancer. 2024;24:535.
    >> Share

  440. GUO Y, Pan Y, Wan J, Gong B, et al
    Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    BMC Cancer. 2024;24:523.
    >> Share

  441. OKAYAMA T, Suzuki K, Morishita S, Inoue J, et al
    Correction: Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:529.
    >> Share

  442. SKURIKHIN E, Ermakova N, Zhukova M, Pan E, et al
    Effects of reprogrammed splenic CD8(+) T-cells in vitro and in mice with spontaneous metastatic Lewis lung carcinoma.
    BMC Cancer. 2024;24:522.
    >> Share

  443. SHI MX, Ding X, Tang L, Cao WJ, et al
    PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
    BMC Cancer. 2024;24:504.
    >> Share

  444. HE M, Jiang W, Li X, Liu H, et al
    25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERbeta/TNFRSF17 axis.
    BMC Cancer. 2024;24:505.
    >> Share

  445. OKAYAMA T, Suzuki K, Morishita S, Inoue J, et al
    Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:495.
    >> Share

  446. XU K, Lu W, Yu A, Wu H, et al
    Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
    BMC Cancer. 2024;24:491.
    >> Share

  447. MIMURA C, Takamiya R, Fujimoto S, Fukui T, et al
    Utility of bronchoscopically obtained frozen cytology pellets for next-generation sequencing.
    BMC Cancer. 2024;24:489.
    >> Share

  448. LI Y, Chen Z, Tian S, Han X, et al
    Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer.
    BMC Cancer. 2024;24:481.
    >> Share

  449. MIAO SN, Chai MQ, Liu XY, Wei CY, et al
    Exercise accelerates recruitment of CD8(+) T cell to promotes anti-tumor immunity in lung cancer via epinephrine.
    BMC Cancer. 2024;24:474.
    >> Share

  450. WU JR, Chen VC, Fang YH, Hsieh CC, et al
    The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarker.
    BMC Cancer. 2024;24:476.
    >> Share

  451. ZHANG D, Liu H, Zhao F, Guo P, et al
    Exploring the relationship between Treg-mediated risk in COPD and lung cancer through Mendelian randomization analysis and scRNA-seq data integration.
    BMC Cancer. 2024;24:453.
    >> Share

  452. HUANG Y, Chen D, Bai Y, Zhang Y, et al
    ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
    BMC Cancer. 2024;24:452.
    >> Share

  453. KONG C, Yin X, Zou J, Ma C, et al
    The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
    BMC Cancer. 2024;24:454.
    >> Share

  454. ARIMURA K, Kammer M, Rahman SMJ, Sheau-Chiann C, et al
    Elucidating the role of EPPK1 in lung adenocarcinoma development.
    BMC Cancer. 2024;24:441.
    >> Share

  455. YANG Y, Xu J, Wang W, Ma M, et al
    A nomogram based on the quantitative and qualitative features of CT imaging for the prediction of the invasiveness of ground glass nodules in lung adenocarcinoma.
    BMC Cancer. 2024;24:438.
    >> Share

  456. JIANG H, Li B, Wu M, Wang Q, et al
    Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
    BMC Cancer. 2024;24:428.
    >> Share

  457. LI H, Li L, Liu Y, Deng Y, et al
    Predictive value of CT and (18)F-FDG PET/CT features on spread through air space in lung adenocarcinoma.
    BMC Cancer. 2024;24:434.
    >> Share

  458. CHEN M, Li R, Kong Y, Shi L, et al
    Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
    BMC Cancer. 2024;24:429.
    >> Share

  459. DIVAN HA, Bittoni MA, Krishna A, Carbone DP, et al
    Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
    BMC Cancer. 2024;24:424.
    >> Share

  460. MENNECIER B, Khalifa J, Descourt R, Greillier L, et al
    Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.
    BMC Cancer. 2024;24:421.
    >> Share

  461. BOUTABBA A, Missaoui F, Dlala A, Kamoun H, et al
    Circulating miR-16-5p, miR-92a-3p and miR-451a are biomarkers of lung cancer in Tunisian patients.
    BMC Cancer. 2024;24:417.
    >> Share

  462. YANG F, Zheng Y, Luo Q, Zhang S, et al
    Knockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway.
    BMC Cancer. 2024;24:408.
    >> Share

  463. SHENG M, Sun R, Fu J, Lu G, et al
    The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    BMC Cancer. 2024;24:399.
    >> Share

    March 2024
  464. ZENG A, Yin Y, Xu Z, Abuduwayiti A, et al
    Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
    BMC Cancer. 2024;24:396.
    >> Share

  465. WEI Q, Deng T, Wu J, Zeng H, et al
    Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
    BMC Cancer. 2024;24:393.
    >> Share

  466. ELBASHEER MMA, Bohrmann B, Chen Y, Lv J, et al
    Reproductive factors and risk of lung cancer among 300,000 Chinese female never-smokers: evidence from the China Kadoorie Biobank study.
    BMC Cancer. 2024;24:384.
    >> Share

  467. XIE M, Gao J, Ma X, Song J, et al
    The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
    BMC Cancer. 2024;24:372.
    >> Share

  468. LI LX, Socinski MA, Kichenadasse G, Karapetis CS, et al
    A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
    BMC Cancer. 2024;24:379.
    >> Share

  469. QI H, Hou Y, Zheng Z, Zheng M, et al
    Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    BMC Cancer. 2024;24:362.
    >> Share

  470. PAN J, Wang J, Tao W, Wang C, et al
    Is low-dose computed tomography for lung cancer screening conveniently accessible in China? A spatial analysis based on cross-sectional survey.
    BMC Cancer. 2024;24:342.
    >> Share

  471. WANG S, Oliveira-Silveira J, Fang G, Kang J, et al
    High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line.
    BMC Cancer. 2024;24:335.
    >> Share

  472. KAHM YJ, Kim IG, Kim RK
    Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is controlled by MCM2.
    BMC Cancer. 2024;24:319.
    >> Share

  473. WU C, Cao B, He G, Li Y, et al
    Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study.
    BMC Cancer. 2024;24:304.
    >> Share

  474. CHENG M, Shao Y, Li L, Jiang M, et al
    Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
    BMC Cancer. 2024;24:312.
    >> Share

  475. ZHOU J, Yu B, Guo P, Wang S, et al
    The insufficiency of CT examination in early detection of central lung squamous cell carcinoma and squamous epithelial precancerous lesions.
    BMC Cancer. 2024;24:299.
    >> Share

  476. WANG Y, Ouyang S, Liu M, Si Q, et al
    Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.
    BMC Cancer. 2024;24:283.
    >> Share

  477. LIU J, Bian T, She B, Liu L, et al
    Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
    BMC Cancer. 2024;24:282.
    >> Share

    February 2024
  478. XU M, Li C, Xiang L, Chen S, et al
    Assessing the causal relationship between 731 immunophenotypes and the risk of lung cancer: a bidirectional mendelian randomization study.
    BMC Cancer. 2024;24:270.
    >> Share

  479. WANG X, Zhao J, Mei T, Liu W, et al
    Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
    BMC Cancer. 2024;24:269.
    >> Share

  480. CHEN K, Li S, Chen M, Jin Z, et al
    Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
    BMC Cancer. 2024;24:257.
    >> Share

  481. CHEN HC, Kuo CY, Chang Y, Tsai DL, et al
    5-Methoxytryptophan enhances the sensitivity of sorafenib on the inhibition of proliferation and metastasis for lung cancer cells.
    BMC Cancer. 2024;24:248.
    >> Share

  482. LANG Y, Lin Y, Deng M, Liu X, et al
    Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
    BMC Cancer. 2024;24:236.
    >> Share

  483. CHENG WC, Lin CC, Liao WC, Lin YC, et al
    The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
    BMC Cancer. 2024;24:228.
    >> Share

  484. HUANG CY, Hsieh MS, Hsieh PC, Wu YK, et al
    Pulmonary rehabilitation improves exercise capacity, health-related quality of life, and cardiopulmonary function in patients with non-small cell lung cancer.
    BMC Cancer. 2024;24:211.
    >> Share

  485. THAMRONGJIRAPAT T, Muntham D, Incharoen P, Trachu N, et al
    Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer.
    BMC Cancer. 2024;24:200.
    >> Share

  486. YIN H, Jia W, Yu J, Zhu H, et al
    Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients.
    BMC Cancer. 2024;24:197.
    >> Share

  487. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
    Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
    BMC Cancer. 2024;24:191.
    >> Share

  488. SHIM YB, Oh BC, Lee EK, Park MH, et al
    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
    BMC Cancer. 2024;24:189.
    >> Share

  489. WANG Y, Ren H
    Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis.
    BMC Cancer. 2024;24:187.
    >> Share

  490. ZHAO M, Shao T, Shao H, Zhou C, et al
    Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:186.
    >> Share

  491. ELSHAMI M, Sawafta N, Mansour A, Alser M, et al
    Anticipated time to seek medical advice for possible lung cancer symptoms and barriers to timely presentation in Palestine: a national cross-sectional study.
    BMC Cancer. 2024;24:183.
    >> Share

  492. YAN N, Zhang H, Shen S, Guo S, et al
    Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
    BMC Cancer. 2024;24:178.
    >> Share

  493. PHAM CP, Nguyen TTH, Do AT, Nguyen TK, et al
    A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    BMC Cancer. 2024;24:176.
    >> Share

  494. WU J, Zhou Y, Xu C, Yang C, et al
    Effectiveness of CT radiomic features combined with clinical factors in predicting prognosis in patients with limited-stage small cell lung cancer.
    BMC Cancer. 2024;24:170.
    >> Share

    January 2024
  495. SHIN S, Moon J, Oum C, Kim S, et al
    Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:152.
    >> Share

  496. DONG W, Yin Y, Yang S, Liu B, et al
    Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
    BMC Cancer. 2024;24:153.
    >> Share

  497. XUE M, Liu J, Li Z, Lu M, et al
    The role of adenocarcinoma subtypes and immunohistochemistry in predicting lymph node metastasis in early invasive lung adenocarcinoma.
    BMC Cancer. 2024;24:139.
    >> Share

  498. LIU JS, Cai YX, He YZ, Xu J, et al
    Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
    BMC Cancer. 2024;24:123.
    >> Share

  499. ZHANG Y, Zhang C, He M, Xing W, et al
    Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.
    BMC Cancer. 2024;24:119.
    >> Share

  500. QIAN J, He Z, Wu Y, Li H, et al
    Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
    BMC Cancer. 2024;24:117.
    >> Share

  501. LI R, Liang H, Li J, Shao Z, et al
    Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
    BMC Cancer. 2024;24:107.
    >> Share

  502. JIA QC, Qin L, Niu Y, Liu L, et al
    Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer.
    BMC Cancer. 2024;24:95.
    >> Share

  503. QIN B, Xin L, Liang C, Li L, et al
    Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    BMC Cancer. 2024;24:100.
    >> Share

  504. LIU W, Du Q, Mei T, Wang J, et al
    Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
    BMC Cancer. 2024;24:94.
    >> Share

  505. LI J, Li L, Tang S, Yu Q, et al
    Novel model integrating computed tomography-based image markers with genetic markers for discriminating radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer receiving radiotherapy: a retrospective multi-center radio
    BMC Cancer. 2024;24:78.
    >> Share

  506. ZHAO Z, Gu S, Yang Y, Wu W, et al
    A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
    BMC Cancer. 2024;24:73.
    >> Share

  507. YANO Y, Abnet CC, Roshandel G, Graf A, et al
    Dental health and lung cancer risk in the Golestan Cohort Study.
    BMC Cancer. 2024;24:74.
    >> Share

  508. KIM TH, Choi JH, Ahn MS, Lee HW, et al
    Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.
    BMC Cancer. 2024;24:70.
    >> Share

  509. CHEN C, Liu H, Li Y, Xu Q, et al
    Downregulation of PTPRT elevates the expression of survivin and promotes the proliferation, migration, and invasion of lung adenocarcinoma.
    BMC Cancer. 2024;24:63.
    >> Share

  510. LIU B, Feng Y, Xie N, Yang Y, et al
    FERMT1 promotes cell migration and invasion in non-small cell lung cancer via regulating PKP3-mediated activation of p38 MAPK signaling.
    BMC Cancer. 2024;24:58.
    >> Share

  511. YAN M, Kang W, Liu X, Yang B, et al
    Prognostic value of plasma microRNAs for non-small cell lung cancer based on data mining models.
    BMC Cancer. 2024;24:52.
    >> Share

  512. LU Y, He W, Huang X, Xiao X, et al
    Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells.
    BMC Cancer. 2024;24:55.
    >> Share

  513. AI F, Zhao J, Yang W, Wan X, et al
    Estimating smoking-attributable lung cancer mortality in Chinese adults from 2000 to 2020: a comparison of three methods.
    BMC Cancer. 2024;24:47.
    >> Share

  514. CHEN LD, Lin L, Chen JZ, Song Y, et al
    Identification of key genes in chronic intermittent hypoxia-induced lung cancer progression based on transcriptome sequencing.
    BMC Cancer. 2024;24:41.
    >> Share

  515. GUO M, Cao Z, Huang Z, Hu S, et al
    The value of CT shape quantification in predicting pathological classification of lung adenocarcinoma.
    BMC Cancer. 2024;24:35.
    >> Share

  516. LIU Y, Han T, Miao R, Zhou J, et al
    RACGAP1 promotes the progression and poor prognosis of lung adenocarcinoma through its effects on the cell cycle and tumor stemness.
    BMC Cancer. 2024;24:7.
    >> Share

  517. ZHAO S, Miao M, Wang Q, Zhao H, et al
    The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
    BMC Cancer. 2024;24:30.
    >> Share

  518. WANG XC, Zhang L, Lin JB, Huang XY, et al
    Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma.
    BMC Cancer. 2024;24:11.
    >> Share

  519. ZHOU F, Wang M, Wang Z, Li W, et al
    Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
    BMC Cancer. 2024;24:28.
    >> Share

    December 2023
  520. DU C, Chen Y, Zhou Y, Zheng D, et al
    Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
    BMC Cancer. 2023;23:1260.
    >> Share

  521. SHEN GY, Huang RZ, Yang SB, Shen RQ, et al
    High SNHG expression may predict a poor lung cancer prognosis based on a meta-analysis.
    BMC Cancer. 2023;23:1243.
    >> Share

  522. ZHENG X, Zhang L, Wu L, Zhao J, et al
    Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
    BMC Cancer. 2023;23:1244.
    >> Share

  523. ZHANG K, Zhang T, Guo Z, Zhao F, et al
    Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.
    BMC Cancer. 2023;23:1240.
    >> Share

  524. VOLPE S, Zaffaroni M, Piperno G, Vincini MG, et al
    Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.
    BMC Cancer. 2023;23:1236.
    >> Share

  525. ARIMURA K, Hiroshima K, Nagashima Y, Nakazawa T, et al
    LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    BMC Cancer. 2023;23:1206.
    >> Share

  526. WANG Y, Li L, Hu J, Zhao Y, et al
    Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    BMC Cancer. 2023;23:1196.
    >> Share

  527. SONG Z, Ma H, Sun H, Li Q, et al
    Construction and validation of a nomogram to predict the overall survival of small cell lung cancer: a multicenter retrospective study in Shandong province, China.
    BMC Cancer. 2023;23:1182.
    >> Share

    November 2023
  528. ZHENG Q, Wang T, Jiang G, Li M, et al
    Immunoglobulin superfamily 6 is a molecule involved in the anti-tumor activity of macrophages in lung adenocarcinoma.
    BMC Cancer. 2023;23:1170.
    >> Share

  529. MILLS S, Donnan P, Buchanan D, Smith BH, et al
    Age and cancer type: associations with increased odds of receiving a late diagnosis in people with advanced cancer.
    BMC Cancer. 2023;23:1174.
    >> Share

  530. DE MORAES FCA, Pasqualotto E, Lopes LM, Cavalcanti Souza ME, et al
    PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
    BMC Cancer. 2023;23:1166.
    >> Share

  531. LIU ZT, Shen JT, Lei YJ, Huang YC, et al
    Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma.
    BMC Cancer. 2023;23:1141.
    >> Share

  532. JIN S, Liu T, Wang W, Li T, et al
    Lymphocyte migration regulation related proteins in urine exosomes may serve as a potential biomarker for lung cancer diagnosis.
    BMC Cancer. 2023;23:1125.
    >> Share

  533. LI S, Wang W, Yu H, Zhang S, et al
    Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    BMC Cancer. 2023;23:1115.
    >> Share

  534. SAMEJIMA H, Kojima K, Fujiwara A, Tokunaga T, et al
    The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study.
    BMC Cancer. 2023;23:1107.
    >> Share

  535. SUN J, Hu JR, Liu CF, Li Y, et al
    ANKRD49 promotes the metastasis of NSCLC via activating JNK-ATF2/c-Jun-MMP-2/9 axis.
    BMC Cancer. 2023;23:1108.
    >> Share

  536. MISAWA S, Denda T, Kodama S, Suzuki T, et al
    Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
    BMC Cancer. 2023;23:1098.
    >> Share

  537. HONG W, Zhang T, Shan C, Li H, et al
    Stroke as initial manifestation of non-small cell lung cancer with Trousseau syndrome.
    BMC Cancer. 2023;23:1096.
    >> Share

  538. LOCOCO F, Boldrini L, Diepriye CD, Evangelista J, et al
    Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study.
    BMC Cancer. 2023;23:1082.
    >> Share

  539. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    >> Share

  540. CHE K, Hong C, He Y, Peng D, et al
    Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China.
    BMC Cancer. 2023;23:1069.
    >> Share

  541. ISAKA T, Adachi H, Murakami K, Miura J, et al
    Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study.
    BMC Cancer. 2023;23:1064.
    >> Share

    October 2023
  542. WANG Y, Yu T, Chen J, Zhao R, et al
    Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity.
    BMC Cancer. 2023;23:1047.
    >> Share

  543. SONG Y, Lin S, Chen J, Dang J, et al
    First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1043.
    >> Share

  544. AFTAB R, Qiang Y, Zhao J, Urrehman Z, et al
    Graph Neural Network for representation learning of lung cancer.
    BMC Cancer. 2023;23:1037.
    >> Share

  545. ZHANG T, Li S, Chang J, Qin Y, et al
    Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    BMC Cancer. 2023;23:1023.
    >> Share

  546. TAFENZI HA, Choulli F, Adjade G, Baladi A, et al
    Development of a well-defined tool to predict the overall survival in lung cancer patients: an African based cohort.
    BMC Cancer. 2023;23:1016.
    >> Share

  547. NAGASAKA M, Zhang SS, Baca Y, Xiu J, et al
    Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
    BMC Cancer. 2023;23:1000.
    >> Share

  548. KIM H, Hwang J, Kim SM, Choi J, et al
    Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease.
    BMC Cancer. 2023;23:992.
    >> Share

  549. PU X, Zhou Y, Kong Y, Chen B, et al
    Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.
    BMC Cancer. 2023;23:982.
    >> Share

  550. ZHAO C, Tong L, Liu B, Qi F, et al
    Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.
    BMC Cancer. 2023;23:973.
    >> Share

  551. YANG Z, Zhong W, Luo Y, Wu C, et al
    The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:962.
    >> Share

  552. GAO Y, Wang X, Zhao X, Zhu C, et al
    Multiphase CT radiomics nomogram for preoperatively predicting the WHO/ISUP nuclear grade of small (< 4 cm) clear cell renal cell carcinoma.
    BMC Cancer. 2023;23:953.
    >> Share

  553. CHEN Y, Gong L, Gu P, Hua Y, et al
    Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.
    BMC Cancer. 2023;23:944.
    >> Share

  554. WANG W, Wang S, Wang M, Ma Y, et al
    Effects of TRAF3 on the proliferation and migration of lung adenocarcinoma depend partly on pyroptosis.
    BMC Cancer. 2023;23:942.
    >> Share

  555. ZHAO Z, Sun Y, Tang J, Yang Y, et al
    LRPPRC regulates malignant behaviors, protects mitochondrial homeostasis, mitochondrial function in osteosarcoma and derived cancer stem-like cells.
    BMC Cancer. 2023;23:935.
    >> Share

  556. ZHANG Y, Qu H, Tian Y, Na F, et al
    PB-LNet: a model for predicting pathological subtypes of pulmonary nodules on CT images.
    BMC Cancer. 2023;23:936.
    >> Share

  557. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    >> Share

  558. AMIN A, Koul AM, Wani UM, Farooq F, et al
    Dissection of paracrine/autocrine interplay in lung tumor microenvironment mimicking cancer cell-monocyte co-culture models reveals proteins that promote inflammation and metastasis.
    BMC Cancer. 2023;23:926.
    >> Share

    September 2023
  559. SHAO CY, Luo J, Ju S, Li CL, et al
    Online decision tools for personalized survival prediction and treatment optimization in elderly patients with lung squamous cell carcinoma: a retrospective cohort study.
    BMC Cancer. 2023;23:920.
    >> Share

  560. LI X, An W, Pan H, Fan Y, et al
    Correction: Wilms' tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p.
    BMC Cancer. 2023;23:909.
    >> Share

  561. WAKUDA K, Kenmotsu H, Sato Y, Nakamura A, et al
    Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH
    BMC Cancer. 2023;23:902.
    >> Share

  562. REN Q, Li Q, Shao C, Zhang P, et al
    Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients.
    BMC Cancer. 2023;23:897.
    >> Share

  563. ALIMBETOV D, Umbayev B, Tsoy A, Begimbetova D, et al
    Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment.
    BMC Cancer. 2023;23:895.
    >> Share

  564. ZHOU T, Wang Z, Qiao C, Wang S, et al
    Sleep disturbances and the risk of lung cancer: a meta-epidemiological study.
    BMC Cancer. 2023;23:884.
    >> Share

  565. LIAO Z, Zheng R, Li N, Shao G, et al
    Development and validation of a risk model with variables related to non-small cell lung cancer in patients with pulmonary nodules: a retrospective study.
    BMC Cancer. 2023;23:872.
    >> Share

  566. BHAT GR, Jamwal RS, Sethi I, Bhat A, et al
    Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India.
    BMC Cancer. 2023;23:874.
    >> Share

  567. SIMIENE J, Dabkeviciene D, Stanciute D, Prokarenkaite R, et al
    Potential of miR-181a-5p and miR-630 as clinical biomarkers in NSCLC.
    BMC Cancer. 2023;23:857.
    >> Share

  568. CHEN CL, Wang ST, Liao WC, Chen CH, et al
    A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.
    BMC Cancer. 2023;23:847.
    >> Share

  569. SON SM, Yun J, Kim DW, Jung YS, et al
    MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma.
    BMC Cancer. 2023;23:843.
    >> Share

  570. KANAOKA K, Sumikawa H, Oyamada S, Tamiya A, et al
    Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.
    BMC Cancer. 2023;23:834.
    >> Share

  571. ROH J, Kim B, Im M, Jang W, et al
    MALAT1-regulated gene expression profiling in lung cancer cell lines.
    BMC Cancer. 2023;23:818.
    >> Share

  572. CHENG G, Wu J, Ji M, Hu W, et al
    TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway.
    BMC Cancer. 2023;23:825.
    >> Share

  573. LI X, An W, Pan H, Fan Y, et al
    Wilms' tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p.
    BMC Cancer. 2023;23:824.
    >> Share

  574. CAI JS, Yang F, Wang X
    Occult lymph node metastasis is not a favorable factor for resected NSCLC patients.
    BMC Cancer. 2023;23:822.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016